Wolfgang Hiddemann

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Procedures

Disorders

Chemicals & Drugs

Concepts & Ideas

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Deshpande Anagha; Pastore Alessandro; Deshpande Aniruddha J; Zimmermann Yvonne; Hutter Grit; Weinkauf Marc; Buske Christian; Hiddemann Wolfgang; Dreyling Martin
3'UTR mediated regulation of the cyclin D1 proto-oncogene.
Seiler Till; Hiddemann Wolfgang
Microenvironmental influences and antigenic stimulation in chronic lymphocytic leukemia.
Metzeler Klaus H; Dufour Annika; Benthaus Tobias; Hummel Manuela; Sauerland Maria-Cristina; Heinecke Achim; Berdel Wolfgang E; Büchner Thomas; Wörmann Bernhard; Mansmann Ulrich; Braess Jan; Spiekermann Karsten; Hiddemann Wolfgang; Buske Christian; Bohlander Stefan K
ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Wolfgang Hiddemann (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Deshpande Anagha; Pastore Alessandro; Deshpande Aniruddha J; Zimmermann Yvonne; Hutter Grit; Weinkauf Marc; Buske Christian; Hiddemann Wolfgang; Dreyling Martin
3'UTR mediated regulation of the cyclin D1 proto-oncogene.
Cell cycle (Georgetown, Tex.) 2009;8(21):3584-92.
2009: Seiler Till; Hiddemann Wolfgang
Microenvironmental influences and antigenic stimulation in chronic lymphocytic leukemia.
Onkologie 2009;32(10):550-1.
2009: Metzeler Klaus H; Dufour Annika; Benthaus Tobias; Hummel Manuela; Sauerland Maria-Cristina; Heinecke Achim; Berdel Wolfgang E; Büchner Thomas; Wörmann Bernhard; Mansmann Ulrich; Braess Jan; Spiekermann Karsten; Hiddemann Wolfgang; Buske Christian; Bohlander Stefan K
ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(30):5031-8.
2009: Hutter G; Scheubner M; Ott G; Zimmermann Y; Hübler K; Roth S; Stilgenbauer S; Kalla J; Stöcklein H; Hiddemann W; Dreyling M
Allelic genotyping reveals a hierarchy of genomic alterations in mantle cell lymphoma associated to cell proliferation.
Annals of hematology 2009;88(9):821-8.
2009: Reibke R; Hausmann A; Cnossen J; Hiddemann W; Spiekermann K; Braess J
[Severe microcytic anemia with megaloblastic changes in the bone marrow. A hematological paradoxon?]
Der Internist 2009;50(7):881-6.
2009: Metzeler Klaus H; Boeck Stefan; Christ Birgit; Hausmann Andreas; Stemmler Hans-Joachim; Parhofer Klaus G; Ostermann Helmut; Hiddemann Wolfgang; Braess Jan
Idiopathic hyperammonemia (IHA) after dose-dense induction chemotherapy for acute myeloid leukemia: Case report and review of the literature.
Leukemia research 2009;33(7):e69-72.
2009: Heilmeier B; Spiekermann K; Bohlander S; Buske C; Feuring-Buske M; Schneider S; Hiddemann W; Braess J
[Modern leukemia diagnosis in adults]
Deutsche medizinische Wochenschrift (1946) 2009;134(23):1222-6.
2009: Weigert Oliver; Weidmann Eckhart; Mueck Rudolf; Bentz Martin; von Schilling Christoph; Rohrberg Robert; Jentsch-Ullrich Kathleen; Hiddemann Wolfgang; Dreyling Martin
A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study.
Leukemia & lymphoma 2009;50(5):716-22.
2009: Winkler Eva C; Reiter-Theil Stella; Lange-Riess Dorothee; Schmahl-Menges Nina; Hiddemann Wolfgang
Patient involvement in decisions to limit treatment: the crucial role of agreement between physician and patient.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(13):2225-30.
2009: Schneider Friederike; Hoster Eva; Unterhalt Michael; Schneider Stephanie; Dufour Annika; Benthaus Tobias; Mellert Gudrun; Zellmeier Evelin; Bohlander Stefan K; Feuring-Buske Michaela; Buske Christian; Braess Jan; Fritsch Susanne; Heinecke Achim; Sauerland Maria C; Berdel Wolfgang E; Buechner Thomas; Woermann Bernhard J; Hiddemann Wolfgang; Spiekermann Karsten
NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS).
Blood 2009;113(21):5250-3.
2009: Reindl Carola; Quentmeier Hilmar; Petropoulos Konstantin; Greif Philipp A; Benthaus Tobias; Argiropoulos Bob; Mellert Gudrun; Vempati Sridhar; Duyster Justus; Buske Christian; Bohlander Stefan K; Humphries Keith R; Hiddemann Wolfgang; Spiekermann Karsten
CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(7):2238-47.
2009: Thoene S; Rawat V P S; Heilmeier B; Hoster E; Metzeler K H; Herold T; Hiddemann W; Gökbuget N; Hoelzer D; Bohlander S K; Feuring-Buske M; Buske C
The homeobox gene CDX2 is aberrantly expressed and associated with an inferior prognosis in patients with acute lymphoblastic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2009;23(4):649-55.
2009: Braess Jan; Spiekermann Karsten; Staib Peter; Grüneisen Andreas; Wörmann Bernhard; Ludwig Wolf-Dieter; Serve Hubert; Reichle Albrecht; Peceny Rudolf; Oruzio Daniel; Schmid Christoph; Schiel Xaver; Hentrich Marcus; Sauerland Christina; Unterhalt Michael; Fiegl Michael; Kern Wolfgang; Buske Christian; Bohlander Stefan; Heinecke Achim; Baurmann Herrad; Beelen Dietrich W; Berdel Wolfgang E; Büchner Thomas; Hiddemann Wolfgang
Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG.
Blood 2009;113(17):3903-10.
2009: Stintzing Sebastian; Heinemann Volker; Moosmann Nicolas; Hiddemann Wolfgang; Jung Andreas; Kirchner Thomas
The treatment of colorectal carcinoma with monoclonal antibodies: the importance of KRAS mutation analysis and EGFR status.
Deutsches Ärzteblatt international 2009;106(12):202-6.
2009: Weinkauf Marc; Zimmermann Yvonne; Hartmann Elena; Rosenwald Andreas; Rieken Malte; Pastore Alessandro; Hutter Grit; Hiddemann Wolfgang; Dreyling Martin
2-D PAGE-based comparison of proteasome inhibitor bortezomib in sensitive and resistant mantle cell lymphoma.
Electrophoresis 2009;30(6):974-86.
2009: Herrmann Annina; Hoster Eva; Zwingers Thomas; Brittinger Günter; Engelhard Marianne; Meusers Peter; Reiser Marcel; Forstpointner Roswitha; Metzner Bernd; Peter Norma; Wörmann Bernhard; Trümper Lorenz; Pfreundschuh Michael; Einsele Hermann; Hiddemann Wolfgang; Unterhalt Michael; Dreyling Martin
Improvement of overall survival in advanced stage mantle cell lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(4):511-8.
2009: Papadaki Christina; Dufour Annika; Seibl Marlene; Schneider Stephanie; Bohlander Stefan K; Zellmeier Evelyn; Mellert Gudrun; Hiddemann Wolfgang; Spiekermann Karsten
Monitoring minimal residual disease in acute myeloid leukaemia with NPM1 mutations by quantitative PCR: clonal evolution is a limiting factor.
British journal of haematology 2009;144(4):517-23.
2009: Büchner Thomas; Berdel Wolfgang E; Haferlach Claudia; Haferlach Torsten; Schnittger Susanne; Müller-Tidow Carsten; Braess Jan; Spiekermann Karsten; Kienast Joachim; Staib Peter; Grüneisen Andreas; Kern Wolfgang; Reichle Albrecht; Maschmeyer Georg; Aul Carlo; Lengfelder Eva; Sauerland Maria-Cristina; Heinecke Achim; Wörmann Bernhard; Hiddemann Wolfgang
Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(1):61-9.
2009: Buske C; Hoster E; Dreyling M; Eimermacher H; Wandt H; Metzner B; Fuchs R; Bittenbring J; Woermann B; Hohloch K; Hess G; Ludwig W-D; Schimke J; Schmitz S; Kneba M; Reiser M; Graeven U; Klapper W; Unterhalt M; Hiddemann W;
The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG).
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2009;23(1):153-61.
2009: Milani Valeria; Stangl Stefan; Issels Rolf; Gehrmann Mathias; Wagner Beate; Hube Kathrin; Mayr Doris; Hiddemann Wolfgang; Molls Michael; Multhoff Gabriele
Anti-tumor activity of patient-derived NK cells after cell-based immunotherapy--a case report.
Journal of translational medicine 2009;7():50.
2008: Lindner L H; Ostermann H; Hiddemann W; Kiani A; Würfel M; Illmer T; Karsch C; Platzbecker U; Ehninger G; Schleyer E
AraU accumulation in patients with renal insufficiency as a potential mechanism for cytarabine neurotoxicity.
International journal of hematology 2008;88(4):381-6.
2008: Metzeler Klaus H; Hummel Manuela; Bloomfield Clara D; Spiekermann Karsten; Braess Jan; Sauerland Maria-Cristina; Heinecke Achim; Radmacher Michael; Marcucci Guido; Whitman Susan P; Maharry Kati; Paschka Peter; Larson Richard A; Berdel Wolfgang E; Büchner Thomas; Wörmann Bernhard; Mansmann Ulrich; Hiddemann Wolfgang; Bohlander Stefan K; Buske Christian;
An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia.
Blood 2008;112(10):4193-201.
2008: Benthaus Tobias; Schneider Friederike; Mellert Gudrun; Zellmeier Evelyn; Schneider Stephanie; Kakadia Purvi M; Hiddemann Wolfgang; Bohlander Stefan K; Feuring-Buske Michaela; Braess Jan; Spiekermann Karsten; Dufour Annika
Rapid and sensitive screening for CEBPA mutations in acute myeloid leukaemia.
British journal of haematology 2008;143(2):230-9.
2008: Dreyling Martin; Hiddemann Wolfgang
Dose-intense treatment of mantle cell lymphoma: can durable remission be achieved?
Current opinion in oncology 2008;20(5):487-94.
2008: Vempati Sridhar; Reindl Carola; Wolf Ulla; Kern Ruth; Petropoulos Konstantin; Naidu Vegi M; Buske Christian; Hiddemann Wolfgang; Kohl Tobias M; Spiekermann Karsten
Transformation by oncogenic mutants and ligand-dependent activation of FLT3 wild-type requires the tyrosine residues 589 and 591.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(14):4437-45.
2008: Fiegl Michael; Lindner Lars H; Juergens Matthias; Eibl Hansjoerg; Hiddemann Wolfgang; Braess Jan
Erufosine, a novel alkylphosphocholine, in acute myeloid leukemia: single activity and combination with other antileukemic drugs.
Cancer chemotherapy and pharmacology 2008;62(2):321-9.
2008: Dreyling M; Weigert O; Hiddemann W;
Current treatment standards and future strategies in mantle cell lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19 Suppl 4():iv41-4.
2008: Böttcher Sebastian; Ritgen Matthias; Buske Sebastian; Gesk Stefan; Klapper Wolfram; Hoster Eva; Hiddemann Wolfgang; Unterhalt Michael; Dreyling Martin; Siebert Reiner; Kneba Michael; Pott Christiane;
Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations.
Haematologica 2008;93(4):551-9.
2008: Bararia D; Trivedi A K; Zada A A Peer; Greif P A; Mulaw M A; Christopeit M; Hiddemann W; Bohlander S K; Behre G
Proteomic identification of the MYST domain histone acetyltransferase TIP60 (HTATIP) as a co-activator of the myeloid transcription factor C/EBPalpha.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2008;22(4):800-7.
2008: Schmid C; Schleuning M; Hentrich M; Markl G E; Gerbitz A; Tischer J; Ledderose G; Oruzio D; Hiddemann W; Kolb H-J
High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission.
Bone marrow transplantation 2008;41(8):721-7.
2008: Petropoulos Konstantin; Arseni Natalia; Schessl Christina; Stadler Christiane R; Rawat Vijay P S; Deshpande Aniruddha J; Heilmeier Bernhard; Hiddemann Wolfgang; Quintanilla-Martinez Leticia; Bohlander Stefan K; Feuring-Buske Michaela; Buske Christian
A novel role for Lef-1, a central transcription mediator of Wnt signaling, in leukemogenesis.
The Journal of experimental medicine 2008;205(3):515-22.
2008: Ahmed Farid; Arseni Natalia; Glimm Hanno; Hiddemann Wolfgang; Buske Christian; Feuring-Buske Michaela
Constitutive expression of the ATP-binding cassette transporter ABCG2 enhances the growth potential of early human hematopoietic progenitors.
Stem cells (Dayton, Ohio) 2008;26(3):810-8.
2008: Determann Olaf; Hoster Eva; Ott German; Wolfram Bernd Heinz; Loddenkemper Christoph; Leo Hansmann Martin; Barth Thomas E F; Unterhalt Michael; Hiddemann Wolfgang; Dreyling Martin; Klapper Wolfram;
Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group.
Blood 2008;111(4):2385-7.
2008: Lindner Lars H; Hossann Martin; Vogeser Michael; Teichert Nicole; Wachholz Kirsten; Eibl Hansjoerg; Hiddemann Wolfgang; Issels Rolf D
Dual role of hexadecylphosphocholine (miltefosine) in thermosensitive liposomes: active ingredient and mediator of drug release.
Journal of controlled release : official journal of the Controlled Release Society 2008;125(2):112-20.
2008: Hoster Eva; Dreyling Martin; Klapper Wolfram; Gisselbrecht Christian; van Hoof Achiel; Kluin-Nelemans Hanneke C; Pfreundschuh Michael; Reiser Marcel; Metzner Bernd; Einsele Hermann; Peter Norma; Jung Wolfram; Wörmann Bernhard; Ludwig Wolf-Dieter; Dührsen Ulrich; Eimermacher Hartmut; Wandt Hannes; Hasford Joerg; Hiddemann Wolfgang; Unterhalt Michael;
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.
Blood 2008;111(2):558-65.
2008: Rawat Vijay P S; Thoene Silvia; Naidu Vegi M; Arseni Natalia; Heilmeier Bernhard; Metzeler Klaus; Petropoulos Konstantin; Deshpande Aniruddha; Quintanilla-Martinez Leticia; Bohlander Stefan K; Spiekermann Karsten; Hiddemann Wolfgang; Feuring-Buske Michaela; Buske Christian
Overexpression of CDX2 perturbs HOX gene expression in murine progenitors depending on its N-terminal domain and is closely correlated with deregulated HOX gene expression in human acute myeloid leukemia.
Blood 2008;111(1):309-19.
2008: Fiegl Michael; Zimmermann Inka; Lorenz Isolde; Hiddemann Wolfgang; Braess Jan
In vitro cross-resistance to nucleoside analogues and inhibitors of topoisomerase 1 and 2 in acute myeloid leukemia.
Annals of hematology 2008;87(1):27-33.
2007: Weinkauf Marc; Christopeit Maximilian; Hiddemann Wolfgang; Dreyling Martin
Proteome- and microarray-based expression analysis of lymphoma cell lines identifies a p53-centered cluster of differentially expressed proteins in mantle cell and follicular lymphoma.
Electrophoresis 2007;28(23):4416-26.
2007: Buske C; Hiddemann W
[The older patient with malignant diseases]
Der Internist 2007;48(11):1206,1208-10.
2007: Schneider F; Bohlander S K; Schneider S; Papadaki C; Kakadyia P; Dufour A; Vempati S; Unterhalt M; Feuring-Buske M; Buske C; Braess J; Wandt H; Hiddemann W; Spiekermann K
AML1-ETO meets JAK2: clinical evidence for the two hit model of leukemogenesis from a myeloproliferative syndrome progressing to acute myeloid leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(10):2199-201.
2007: Büchner Thomas; Krug Utz; Berdel Wolfgang E; Heinecke Achim; Sauerland Maria Cristina; Wörmann Bernhard; Hiddemann Wolfgang
Maintenance for acute myeloid leukemia revisited.
Current treatment options in oncology 2007;8(4):296-304.
2007: Klapper Wolfram; Hoster Eva; Rölver Lars; Schrader Carsten; Janssen Dirk; Tiemann Markus; Bernd Heinz-Wolfram; Determann Olaf; Hansmann Martin-Leo; Möller Peter; Feller Alfred; Stein Harald; Wacker Hans-Heinrich; Dreyling Martin; Unterhalt Michael; Hiddemann Wolfgang; Ott German;
Tumor sclerosis but not cell proliferation or malignancy grade is a prognostic marker in advanced-stage follicular lymphoma: the German Low Grade Lymphoma Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(22):3330-6.
2007: Kohl T M; Hellinger C; Ahmed F; Buske C; Hiddemann W; Bohlander S K; Spiekermann K
BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(8):1763-72.
2007: Weide Rudolf; Hess Georg; Köppler Hubert; Heymanns Jochen; Thomalla Jörg; Aldaoud Ali; Losem Christoph; Schmitz Stefan; Haak Ursula; Huber Christoph; Unterhalt Michael; Hiddemann Wolfgang; Dreyling Martin;
High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
Leukemia & lymphoma 2007;48(7):1299-306.
2007: Vempati Sridhar; Reindl Carola; Kaza Seshu Kumar; Kern Ruth; Malamoussi Theodora; Dugas Martin; Mellert Gudrun; Schnittger Susanne; Hiddemann Wolfgang; Spiekermann Karsten
Arginine 595 is duplicated in patients with acute leukemias carrying internal tandem duplications of FLT3 and modulates its transforming potential.
Blood 2007;110(2):686-94.
2007: Hiddemann W
[High performance medicine and humanism. A contradiction?]
Der Internist 2007;48 Suppl 1():S17-9.
2007: Weisser M; Haferlach C; Hiddemann W; Schnittger S
The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(6):1177-82.
2007: Hiddemann Wolfgang
[High-performance medicine and humanitarian principles]
Medizinische Klinik (Munich, Germany : 1983) 2007;102(5):331-5.
2007: Schneider F; Braess J; Feuring-Buske M; Hiddemann W; Spiekermann K
[Elevated Hemoglobin--polyglobulia or polycythemia?]
MMW Fortschritte der Medizin 2007;149(15):40-1, 43.
2007: Metzeler K H; Braess J; Spiekermann K; Bohlander S K; Hiddemann W; Buske C; Feuring-Buske M
[Fortuitous finding: thrombocytopenia and thrombocytosis]
MMW Fortschritte der Medizin 2007;149(15):34-5, 37.
2007: Fritsch Susanne; Buske Christian; Wörmann Bernhard; Wedding Ulrich; Hiddemann Wolfgang; Spiekermann Karsten
[Therapy of acute myeloid leukemia (AML) for medically non-fit patients]
Medizinische Klinik (Munich, Germany : 1983) 2007;102(4):324-9.
2007: Fiegl Michael; Hiddemann Wolfgang; Braess Jan
[Current therapeutic strategies in the management of acute myeloid leukemia]
Medizinische Klinik (Munich, Germany : 1983) 2007;102(4):309-16.
2007: Heilmeier Bernhard; Buske Christian; Spiekermann Karsten; Bohlander Stefan; Feuring-Buske Michaela; Hiddemann Wolfgang; Braess Jan
[Diagnostics, classification and prognostic criteria of acute myeloid leukemia]
Medizinische Klinik (Munich, Germany : 1983) 2007;102(4):296-308.
2007: Christ Oliver; Feuring-Buske Michaela; Hiddemann Wolfgang; Buske Christian
[Pathobiology of acute myeloid leukemia]
Medizinische Klinik (Munich, Germany : 1983) 2007;102(4):290-5.
2007: Buske C; Hiddemann W
[Malignant lymphoma--there are still many open questions]
Der Internist 2007;48(4):349-50.
2007: Dreyling M; Unterhalt M; Weigert O; Hiddemann W
[Therapy of mantle cell lymphoma]
Der Internist 2007;48(4):382-8.
2007: Fiegl Michael; Juergens Matthias; Hiddemann Wolfgang; Braess Jan
Cytotoxic activity of the third-generation bisphosphonate zoledronic acid in acute myeloid leukemia.
Leukemia research 2007;31(4):531-9.
2007: Weigert O; Pastore A; Rieken M; Lang N; Hiddemann W; Dreyling M
Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(3):524-8.
2007: Trivedi A K; Bararia D; Christopeit M; Peerzada A A; Singh S M; Kieser A; Hiddemann W; Behre H M; Behre G
Proteomic identification of C/EBP-DBD multiprotein complex: JNK1 activates stem cell regulator C/EBPalpha by inhibiting its ubiquitination.
Oncogene 2007;26(12):1789-801.
2007: Hiddemann Wolfgang; Buske Christian; Dreyling Martin; Weigert Oliver; Lenz Georg; Unterhalt Michael
Current management of follicular lymphomas.
British journal of haematology 2007;136(2):191-202.
2007: Nickenig C; Dreyling M; Hoster E; Ludwig W-D; Dörken B; Freund M; Huber C; Ganser A; Trümper L; Forstpointner R; Unterhalt M; Hiddemann W;
Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas--results of a randomized comparison by the German Low-Grade Lymphoma Study Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(1):136-42.
2007: Weigert Oliver; Unterhalt Michael; Hiddemann Wolfgang; Dreyling Martin
Current management of mantle cell lymphoma.
Drugs 2007;67(12):1689-702.
2006: Weisser Martin; Kern Wolfgang; Schoch Claudia; Tschulik Claudia; Hiddemann Wolfgang; Haferlach Torsten; Schnittger Susanne
Reverse transcriptase-polymerase chain reaction based quantification of the combined MDS-EVI1/EVI1 gene in acute myeloid leukemia.
Leukemia & lymphoma 2006;47(12):2645-7.
2006: Wittmann Marc; Vollmer Tanja; Schweiger Claudia; Hiddemann Wolfgang
The relation between the experience of time and psychological distress in patients with hematological malignancies.
Palliative & supportive care 2006;4(4):357-63.
2006: Zada A A; Pulikkan J A; Bararia D; Geletu M; Trivedi A K; Balkhi M Y; Hiddemann W D; Tenen D G; Behre H M; Behre G
Proteomic discovery of Max as a novel interacting partner of C/EBPalpha: a Myc/Max/Mad link.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2006;20(12):2137-46.
2006: Forstpointner Roswitha; Unterhalt Michael; Dreyling Martin; Böck Hans-Peter; Repp Roland; Wandt Hannes; Pott Christiane; Seymour John F; Metzner Bernd; Hänel Annette; Lehmann Tanja; Hartmann Frank; Einsele Hermann; Hiddemann Wolfgang;
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG).
Blood 2006;108(13):4003-8.
2006: Deshpande Aniruddha J; Cusan Monica; Rawat Vijay P S; Reuter Hendrik; Krause Alexandre; Pott Christiane; Quintanilla-Martinez Leticia; Kakadia Purvi; Kuchenbauer Florian; Ahmed Farid; Delabesse Eric; Hahn Meinhard; Lichter Peter; Kneba Michael; Hiddemann Wolfgang; Macintyre Elizabeth; Mecucci Cristina; Ludwig Wolf-Dieter; Humphries R Keith; Bohlander Stefan K; Feuring-Buske Michaela; Buske Christian
Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM/AF10-positive leukemia.
Cancer cell 2006;10(5):363-74.
2006: Weinkauf Marc; Hiddemann Wolfgang; Dreyling Martin
Sample pooling in 2-D gel electrophoresis: a new approach to reduce nonspecific expression background.
Electrophoresis 2006;27(22):4555-8.
2006: Hiddemann Wolfgang
["We need new alliances." Interview by Hildegrad Kaulen]
Deutsche medizinische Wochenschrift (1946) 2006;Suppl 1():8-9.
2006: Fritsch S; Metzeler K; Hiddemann W; Buske C
[Diagnostics and therapy of acute myeloid leukemia]
Deutsche medizinische Wochenschrift (1946) 2006;131(43):2401-6.
2006: Hiddemann W; Unterhalt M
Current treatment strategies in follicular lymphomas.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17 Suppl 10():x155-9.
2006: Kuchenbauer F; Schnittger S; Look T; Gilliland G; Tenen D; Haferlach T; Hiddemann W; Buske C; Schoch C
Identification of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukaemia with t(8;21)/AML1-ETO.
British journal of haematology 2006;134(6):616-9.
2006: Weigert Oliver; Dreyling Martin; Unterhalt Michael; Hiddemann Wolfgang; Buske Christian
Investigational strategies in autologous stem cell transplantation for follicular lymphoma.
Current oncology reports 2006;8(5):368-75.
2006: Nickenig Christina; Dreyling Martin; Hoster Eva; Pfreundschuh Michael; Trumper Lorenz; Reiser Marcel; Wandt Hannes; Lengfelder Eva; Unterhalt Michael; Hiddemann Wolfgang;
Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.
Cancer 2006;107(5):1014-22.
2006: Buske Christian; Hoster Eva; Dreyling Martin; Hasford Joerg; Unterhalt Michael; Hiddemann Wolfgang
The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome.
Blood 2006;108(5):1504-8.
2006: Weigert Oliver; Illidge Tim; Hiddemann Wolfgang; Dreyling Martin
Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma.
Cancer 2006;107(4):686-95.
2006: Schmid Christoph; Schleuning Michael; Schwerdtfeger Rainer; Hertenstein Bernd; Mischak-Weissinger Eva; Bunjes Donald; Harsdorf Stephanie V; Scheid Christoph; Holtick Udo; Greinix Hildegard; Keil Felix; Schneider Barbara; Sandherr Michael; Bug Gesine; Tischer Johanna; Ledderose Georg; Hallek Michael; Hiddemann Wolfgang; Kolb Hans-Jochem
Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation.
Blood 2006;108(3):1092-9.
2006: Schiel X; Link H; Maschmeyer G; Glass B; Cornely O A; Buchheidt D; Wilhelm M; Silling G; Helmerking M; Hiddemann W; Ostermann H; Hentrich M
A prospective, randomized multicenter trial of the empirical addition of antifungal therapy for febrile neutropenic cancer patients: results of the Paul Ehrlich Society for Chemotherapy (PEG) Multicenter Trial II.
Infection 2006;34(3):118-26.
2006: Metzeler K; Fritsch S; Buske C; Hiddemann W
[Acute myeloid leukemia -- on the way towards pathogenesis-oriented treatment]
Deutsche medizinische Wochenschrift (1946) 2006;131(25-26):1466-8.
2006: Büchner Thomas; Berdel Wolfgang E; Schoch Claudia; Haferlach Torsten; Serve Hubert L; Kienast Joachim; Schnittger Susanne; Kern Wolfgang; Tchinda Joelle; Reichle Albrecht; Lengfelder Eva; Staib Peter; Ludwig Wolf-Dieter; Aul Carlo; Eimermacher Hartmut; Balleisen Leopold; Sauerland Maria-Cristina; Heinecke Achim; Wörmann Bernhard; Hiddemann Wolfgang
Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(16):2480-9.
2006: Falini Brunangelo; Bolli Niccolò; Shan Jing; Martelli Maria Paola; Liso Arcangelo; Pucciarini Alessandra; Bigerna Barbara; Pasqualucci Laura; Mannucci Roberta; Rosati Roberto; Gorello Paolo; Diverio Daniela; Roti Giovanni; Tiacci Enrico; Cazzaniga Giovanni; Biondi Andrea; Schnittger Suzanne; Haferlach Torsten; Hiddemann Wolfgang; Martelli Massimo F; Gu Wei; Mecucci Cristina; Nicoletti Ildo
Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML.
Blood 2006;107(11):4514-23.
2006: Feuring-Buske M; Hiddemann W
[Stem cell therapy]
Der Internist 2006;47(5):457-8.
2006: Hentrich Marcus; Fehnle Karl; Ostermann Helmut; Kienast Joachim; Cornely Oliver; Salat Christoph; Ubelacker Ralf; Buchheidt Dieter; Behre Gerhard; Hiddemann Wolfgang; Schiel Xaver
IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple-center trial.
Critical care medicine 2006;34(5):1319-25.
2006: Reindl Carola; Bagrintseva Ksenia; Vempati Sridhar; Schnittger Susanne; Ellwart Joachim W; Wenig Katja; Hopfner Karl-Peter; Hiddemann Wolfgang; Spiekermann Karsten
Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML.
Blood 2006;107(9):3700-7.
2006: Schnittger Susanne; Kohl Tobias M; Leopold Nina; Schoch Claudia; Wichmann H-Erich; Kern Wolfgang; Lohse Peter; Hiddemann Wolfgang; Haferlach Torsten; Spiekermann Karsten
D324N single-nucleotide polymorphism in the FLT3 gene is associated with higher risk of myeloid leukemias.
Genes, chromosomes & cancer 2006;45(4):332-7.
2006: Buske Christian; Hiddemann Wolfgang
Rituximab maintenance therapy in indolent NHL: a clinical review.
Leukemia research 2006;30 Suppl 1():S11-5.
2006: Hiddemann Wolfgang
Rituximab maintenance therapy in follicular lymphoma comes of age.
Leukemia research 2006;30 Suppl 1():S1-2.
2006: Pott Christiane; Schrader Carsten; Gesk Stefan; Harder Lana; Tiemann Markus; Raff Thorsten; Brüggemann Monika; Ritgen Matthias; Gahn Benedikt; Unterhalt Michael; Dreyling Martin; Hiddemann Wolfgang; Siebert Reiner; Dreger Peter; Kneba Michael
Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma.
Blood 2006;107(6):2271-8.
2006: Schnittger Susanne; Kohl Tobias M; Haferlach Torsten; Kern Wolfgang; Hiddemann Wolfgang; Spiekermann Karsten; Schoch Claudia
KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival.
Blood 2006;107(5):1791-9.
2006: Radomska Hanna S; Bassères Daniela S; Zheng Rui; Zhang Pu; Dayaram Tajhal; Yamamoto Yukiya; Sternberg David W; Lokker Nathalie; Giese Neill A; Bohlander Stefan K; Schnittger Susanne; Delmotte Marie-Hélène; Davis Roger J; Small Donald; Hiddemann Wolfgang; Gilliland D Gary; Tenen Daniel G
Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations.
The Journal of experimental medicine 2006;203(2):371-81.
2006: Bacher Ulrike; Kern Wolfgang; Schoch Claudia; Schnittger Susanne; Hiddemann Wolfgang; Haferlach Torsten
Evaluation of complete disease remission in acute myeloid leukemia: a prospective study based on cytomorphology, interphase fluorescence in situ hybridization, and immunophenotyping during follow-up in patients with acute myeloid leukemia.
Cancer 2006;106(4):839-47.
2006: Hutter Grit; Scheubner Miriam; Zimmermann Yvonne; Kalla Joerg; Katzenberger Tiemo; Hübler Karin; Roth Sabine; Hiddemann Wolfgang; Ott German; Dreyling Martin
Differential effect of epigenetic alterations and genomic deletions of CDK inhibitors [p16(INK4a), p15(INK4b), p14(ARF)] in mantle cell lymphoma.
Genes, chromosomes & cancer 2006;45(2):203-10.
2006: Buske Christian; Weigert Oliver; Dreyling Martin; Unterhalt Michael; Hiddemann Wolfgang
Current status and perspective of antibody therapy in follicular lymphoma.
Haematologica 2006;91(1):104-12.
2006: Schlemmer Marcus; Wendtner Clemens-Martin; Falk Martin; Abdel-Rahman Sultan; Licht Thomas; Baumert Jens; Straka Christian; Hentrich Marcus; Salat Christoph; Hiddemann Wolfgang; Issels Rolf-Dieter
Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas.
Oncology 2006;71(1-2):32-9.
2006: Kohlmann Alexander; Kern Wolfgang; Hiddemann Wolfgang; Haferlach Torsten
Classification of AML by DNA-oligonucleotide microarrays.
Methods in molecular medicine 2006;125():213-40.
2005: Kuchenbauer Florian; Kern Wolfgang; Schoch Claudia; Kohlmann Alexander; Hiddemann Wolfgang; Haferlach Torsten; Schnittger Susanne
Detailed analysis of FLT3 expression levels in acute myeloid leukemia.
Haematologica 2005;90(12):1617-25.
2005: Hiddemann Wolfgang; Kneba Michael; Dreyling Martin; Schmitz Norbert; Lengfelder Eva; Schmits Rudolf; Reiser Marcel; Metzner Bernd; Harder Harriet; Hegewisch-Becker Susanna; Fischer Thomas; Kropff Martin; Reis Hans-Edgar; Freund Mathias; Wörmann Bernhard; Fuchs Roland; Planker Manfred; Schimke Jörg; Eimermacher Hartmut; Trümper Lorenz; Aldaoud Ali; Parwaresch Reza; Unterhalt Michael
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.
Blood 2005;106(12):3725-32.
2005: Schnittger Susanne; Schoch Claudia; Kern Wolfgang; Mecucci Cristina; Tschulik Claudia; Martelli Massimo F; Haferlach Torsten; Hiddemann Wolfgang; Falini Brunangelo
Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.
Blood 2005;106(12):3733-9.
2005: Arseni Natalia; Ahmed Farid; Hiddemann Wolfgang; Buske Christian; Feuring-Buske Michaela
Effects of the protein tyrosine kinase inhibitor, SU5614, on leukemic and normal stem cells.
Haematologica 2005;90(11):1577-8.
2005: Bacher Ulrike; Kern Wolfgang; Schnittger Susanne; Hiddemann Wolfgang; Haferlach Torsten; Schoch Claudia
Population-based age-specific incidences of cytogenetic subgroups of acute myeloid leukemia.
Haematologica 2005;90(11):1502-10.
2005: Büchner Thomas; Berdel Wolfgang E; Wörmann Bernhard; Schoch Claudia; Haferlach Torsten; Schnittger Susanne; Kern Wolfgang; Aul Carlo; Lengfelder Eva; Schumacher Andrea; Reichle Albrecht; Staib Peter; Balleisen Leopold; Eimermacher Hartmut; Grüneisen Andreas; Rasche Herbert; Sauerland Maria Cristina; Heinecke Achim; Mesters Rolf M; Serve Hubert L; Kienast Joachim; Hiddemann Wolfgang
Treatment of older patients with AML.
Critical reviews in oncology/hematology 2005;56(2):247-59.
2005: Hiddemann W; Spiekermann K; Buske C; Feuring-Buske M; Braess J; Haferlach T; Schoch C; Kern W; Schnittger S; Berdel W; Wörmann B; Heinecke A; Sauerland C; Büchner Th;
Towards a pathogenesis-oriented therapy of acute myeloid leukemia.
Critical reviews in oncology/hematology 2005;56(2):235-45.
2005: Bacher Ulrike; Kern Wolfgang; Schnittger Susanne; Hiddemann Wolfgang; Schoch Claudia; Haferlach Torsten
Further correlations of morphology according to FAB and WHO classification to cytogenetics in de novo acute myeloid leukemia: a study on 2,235 patients.
Annals of hematology 2005;84(12):785-91.
2005: Braess Jan; Fiegl Michael; Lorenz Isolde; Waxenberger Karin; Hiddemann Wolfgang
Modeling the pharmacodynamics of highly schedule-dependent agents: exemplified by cytarabine-based regimens in acute myeloid leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(20):7415-25.
2005: Tiemann Markus; Schrader Carsten; Klapper Wolfram; Dreyling Martin H; Campo Elias; Norton Andrew; Berger Francoise; Kluin Philip; Ott German; Pileri Stephano; Pedrinis Ennio; Feller Alfred C; Merz Hartmut; Janssen Dirk; Hansmann Martin L; Krieken Han; Möller Peter; Stein Harald; Unterhalt Michael; Hiddemann Wolfgang; Parwaresch Reza;
Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network.
British journal of haematology 2005;131(1):29-38.
2005: Dreyling M; Buske C; Hiddemann W
[Up-to-date treatment of follicular lymphomas]
Deutsche medizinische Wochenschrift (1946) 2005;130(38):2149-54.
2005: Hiddemann Wolfgang; Buske Christian; Dreyling Martin; Weigert Oliver; Lenz Georg; Forstpointner Roswitha; Nickenig Christina; Unterhalt Michael
Treatment strategies in follicular lymphomas: current status and future perspectives.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(26):6394-9.
2005: Arnold Rudolf; Rinke Anja; Klose Klaus-Jochen; Müller Hans-Helge; Wied Matthias; Zamzow Karin; Schmidt Christina; Schade-Brittinger Carmen; Barth Peter; Moll Roland; Koller Michael; Unterhalt Michael; Hiddemann Wolfgang; Schmidt-Lauber Martin; Pavel Marianne; Arnold Christian N
Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2005;3(8):761-71.
2005: Hiddemann W; Heinemann V
[Current progress in therapy of malignant diseases]
Deutsche medizinische Wochenschrift (1946) 2005;130(31-32):1837-40.
2005: Hölzel Michael; Rohrmoser Michaela; Schlee Martin; Grimm Thomas; Harasim Thomas; Malamoussi Anastassia; Gruber-Eber Anita; Kremmer Elisabeth; Hiddemann Wolfgang; Bornkamm Georg W; Eick Dirk
Mammalian WDR12 is a novel member of the Pes1-Bop1 complex and is required for ribosome biogenesis and cell proliferation.
The Journal of cell biology 2005;170(3):367-78.
2005: Schessl Christina; Rawat Vijay P S; Cusan Monica; Deshpande Aniruddha; Kohl Tobias M; Rosten Patricia M; Spiekermann Karsten; Humphries R Keith; Schnittger Susanne; Kern Wolfgang; Hiddemann Wolfgang; Quintanilla-Martinez Leticia; Bohlander Stefan K; Feuring-Buske Michaela; Buske Christian
The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice.
The Journal of clinical investigation 2005;115(8):2159-68.
2005: Spiekermann K; Hiddemann W
[Molecular target structures in oncology]
Der Internist 2005;46(8):847-8, 850-4, 856-60.
2005: Weisser M; Kern W; Rauhut S; Schoch C; Hiddemann W; Haferlach T; Schnittger S
Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(8):1416-23.
2005: Haferlach Torsten; Kohlmann Alexander; Schnittger Susanne; Dugas Martin; Hiddemann Wolfgang; Kern Wolfgang; Schoch Claudia
Global approach to the diagnosis of leukemia using gene expression profiling.
Blood 2005;106(4):1189-98.
2005: Kuchenbauer Florian; Schoch Claudia; Kern Wolfgang; Hiddemann Wolfgang; Haferlach Torsten; Schnittger Susanne
Impact of FLT3 mutations and promyelocytic leukaemia-breakpoint on clinical characteristics and prognosis in acute promyelocytic leukaemia.
British journal of haematology 2005;130(2):196-202.
2005: Weisser Martin; Kern Wolfgang; Schoch Claudia; Hiddemann Wolfgang; Haferlach Torsten; Schnittger Susanne
Risk assessment by monitoring expression levels of partial tandem duplications in the MLL gene in acute myeloid leukemia during therapy.
Haematologica 2005;90(7):881-9.
2005: Buske Christian; Dreyling Martin; Unterhalt Michael; Hiddemann Wolfgang
Transplantation strategies for patients with follicular lymphoma.
Current opinion in hematology 2005;12(4):266-72.
2005: Schoch C; Kohlmann A; Dugas M; Kern W; Hiddemann W; Schnittger S; Haferlach T
Genomic gains and losses influence expression levels of genes located within the affected regions: a study on acute myeloid leukemias with trisomy 8, 11, or 13, monosomy 7, or deletion 5q.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(7):1224-8.
2005: Schoch Claudia; Kern Wolfgang; Kohlmann Alexander; Hiddemann Wolfgang; Schnittger Susanne; Haferlach Torsten
Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile.
Genes, chromosomes & cancer 2005;43(3):227-38.
2005: Kohlmann A; Schoch C; Dugas M; Schnittger S; Hiddemann W; Kern W; Haferlach T
New insights into MLL gene rearranged acute leukemias using gene expression profiling: shared pathways, lineage commitment, and partner genes.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(6):953-64.
2005: Haferlach Torsten; Kohlmann Alexander; Schnittger Susanne; Dugas Martin; Hiddemann Wolfgang; Kern Wolfgang; Schoch Claudia
AML M3 and AML M3 variant each have a distinct gene expression signature but also share patterns different from other genetically defined AML subtypes.
Genes, chromosomes & cancer 2005;43(2):113-27.
2005: Herzog Gerhard; Lu-Hesselmann Juxian; Zimmermann Yvonne; Haferlach Torsten; Hiddemann Wolfgang; Dreyling Martin
Microsatellite instability and p53 mutations are characteristic of subgroups of acute myeloid leukemia but independent events.
Haematologica 2005;90(5):693-5.
2005: Bagrintseva Ksenia; Geisenhof Stefanie; Kern Ruth; Eichenlaub Sabine; Reindl Carola; Ellwart Joachim W; Hiddemann Wolfgang; Spiekermann Karsten
FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L).
Blood 2005;105(9):3679-85.
2005: Spiekermann K; Hiddemann W; Schnittger S
[Mutations of the gene coding for the receptor tyrosine kinase FLT3 in acute myeloid leukemia. Significance as the disease-specific molecular marker for diagnosis, prognosis and innovative therapy approaches]
Deutsche medizinische Wochenschrift (1946) 2005;130(16):1020-5.
2005: Bacher Ulrike; Schnittger Susanne; Kern Wolfgang; Hiddemann Wolfgang; Haferlach Torsten; Schoch Claudia
The incidence of submicroscopic deletions in reciprocal translocations is similar in acute myeloid leukemia, BCR-ABL positive acute lymphoblastic leukemia, and chronic myeloid leukemia.
Haematologica 2005;90(4):558-9.
2005: Bacher Ulrike; Haferlach Torsten; Kern Wolfgang; Hiddemann Wolfgang; Schnittger Susanne; Schoch Claudia
Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information.
Annals of hematology 2005;84(4):250-7.
2005: Kohl Tobias M; Schnittger Susanne; Ellwart Joachim W; Hiddemann Wolfgang; Spiekermann Karsten
KIT exon 8 mutations associated with core-binding factor (CBF)-acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor.
Blood 2005;105(8):3319-21.
2005: Dreyling Martin; Lenz Georg; Hoster Eva; Van Hoof Achiel; Gisselbrecht Christian; Schmits Rudolf; Metzner Bernd; Truemper Lorenz; Reiser Marcel; Steinhauer Hjalmar; Boiron Jean-Michel; Boogaerts Marc A; Aldaoud Ali; Silingardi Vittorio; Kluin-Nelemans Hanneke C; Hasford Joerg; Parwaresch Reza; Unterhalt Michael; Hiddemann Wolfgang
Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network.
Blood 2005;105(7):2677-84.
2005: Fiegl Michael; Büchner Thomas; Hiddemann Wolfgang; Braess Jan
A phase I/II study of oral etoposide and idarubicin in elderly patients with high-risk acute myeloid leukemia unable to undergo intensive chemotherapy.
Annals of hematology 2005;84(4):227-31.
2005: Lenz Georg; Dreyling Martin; Hoster Eva; Wörmann Bernhard; Dührsen Ulrich; Metzner Bernd; Eimermacher Hartmut; Neubauer Andreas; Wandt Hannes; Steinhauer Hjalmar; Martin Sonja; Heidemann Else; Aldaoud Ali; Parwaresch Reza; Hasford Joerg; Unterhalt Michael; Hiddemann Wolfgang
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(9):1984-92.
2005: Bacher Ulrike; Kern Wolfgang; Schnittger Susanne; Hiddemann Wolfgang; Schoch Claudia; Haferlach Torsten
Blast count and cytogenetics correlate and are useful parameters for the evaluation of different phases in chronic myeloid leukemia.
Leukemia & lymphoma 2005;46(3):357-66.
2005: Bacher Ulrike; Haferlach Torsten; Hiddemann Wolfgang; Schnittger Susanne; Kern Wolfgang; Schoch Claudia
Additional clonal abnormalities in Philadelphia-positive ALL and CML demonstrate a different cytogenetic pattern at diagnosis and follow different pathways at progression.
Cancer genetics and cytogenetics 2005;157(1):53-61.
2005: Neben Kai; Schnittger Susanne; Brors Benedikt; Tews Björn; Kokocinski Felix; Haferlach Torsten; Müller Jasmin; Hahn Meinhard; Hiddemann Wolfgang; Eils Roland; Lichter Peter; Schoch Claudia
Distinct gene expression patterns associated with FLT3- and NRAS-activating mutations in acute myeloid leukemia with normal karyotype.
Oncogene 2005;24(9):1580-8.
2005: Buske Christian; Dreyling Martin; Unterhalt Michael; Hiddemann Wolfgang
[Monoclonal antibody therapy for malignant lymphoma]
Medizinische Klinik (Munich, Germany : 1983) 2005;100(1):14-24.
2005: Hentrich Marcus; Oruzio Daniel; Jäger Gundula; Schlemmer Marcus; Schleuning Michael; Schiel Xaver; Hiddemann Wolfgang; Kolb Hans-Jochem
Impact of human herpesvirus-6 after haematopoietic stem cell transplantation.
British journal of haematology 2005;128(1):66-72.
2005: Krych M; Hiddemann W
[Oncological emergencies]
Der Internist 2005;46(1):7-8.
2005: Buechner Thomas; Berdel Wolfgang E; Schoch Claudia; Haferlach Torsten; Serve Hubert L; Schnittger Susanne; Kern Wolfgang; Tchinda Joelle; Reichle Albrecht; Staib Peter; Ludwig Wolf-Dieter; Aul Carlo; Sauerland Maria-Cristina; Heinecke Achim; Woermann Bernhard; Hiddemann Wolfgang;
Treatment of AML in biological subgroups.
Hematology (Amsterdam, Netherlands) 2005;10 Suppl 1():281-85.
2005: Dreyling M; Buske C; Hiddemann W
Advances in molecular biology diagnostic and treatment of B-cell malignancies: indolent B-cell lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16 Suppl 2():ii99-104.
2004: Lenz Georg; Dreyling Martin; Schiegnitz Eva; Haferlach Torsten; Hasford Joerg; Unterhalt Michael; Hiddemann Wolfgang
Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(24):4926-33.
2004: Buske C; Dreyling M; Unterhalt M; Hiddemann W
[Monoclonal antibody treatment of malignant lymphoma]
Der Internist 2004;45(12):1370-7.
2004: Lenz G; Dreyling M; Unterhalt M; Hiddemann W
[Current strategies in the treatment of advanced stage mantle cell lymphoma]
Deutsche medizinische Wochenschrift (1946) 2004;129(45):2429-33.
2004: Klaus Mirjam; Haferlach Torsten; Schnittger Susanne; Kern Wolfgang; Hiddemann Wolfgang; Schoch Claudia
Cytogenetic profile in de novo acute myeloid leukemia with FAB subtypes M0, M1, and M2: a study based on 652 cases analyzed with morphology, cytogenetics, and fluorescence in situ hybridization.
Cancer genetics and cytogenetics 2004;155(1):47-56.
2004: Voskova Daniela; Schoch Claudia; Schnittger Susanne; Hiddemann Wolfgang; Haferlach Torsten; Kern Wolfgang
Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic, and molecular genetic findings.
Cytometry. Part B, Clinical cytometry 2004;62(1):25-38.
2004: Kern Wolfgang; Voskova Daniela; Schoch Claudia; Hiddemann Wolfgang; Schnittger Susanne; Haferlach Torsten
Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia.
Blood 2004;104(10):3078-85.
2004: Forstpointner Roswitha; Dreyling Martin; Repp Roland; Hermann Sandra; Hänel Annette; Metzner Bernd; Pott Christiane; Hartmann Frank; Rothmann Frank; Rohrberg Robert; Böck Hans-Peter; Wandt Hannes; Unterhalt Michael; Hiddemann Wolfgang;
The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.
Blood 2004;104(10):3064-71.
2004: Lenz Georg; Dreyling Martin; Schiegnitz Eva; Forstpointner Roswitha; Wandt Hannes; Freund Mathias; Hess Georg; Truemper Lorenz; Diehl Volker; Kropff Martin; Kneba Michael; Schmitz Norbert; Metzner Bernd; Pfirrmann Markus; Unterhalt Michael; Hiddemann Wolfgang;
Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group.
Blood 2004;104(9):2667-74.
2004: Kuchenbauer Florian; Strassburg Christian P; Vogel Arndt; Hiddemann Wolfgang; Beuers Ulrich
UGT1A7 polymorphisms, polycyclic aromatic hydrocarbons and the development of hepatocellular cancer.
Hepatology (Baltimore, Md.) 2004;40(4):1021.
2004: Lenz Georg; Hutter Grit; Hiddemann Wolfgang; Dreyling Martin
Promoter methylation and expression of DNA repair genes hMLH1 and MGMT in acute myeloid leukemia.
Annals of hematology 2004;83(10):628-33.
2004: Schoch Claudia; Kern Wolfgang; Schnittger Susanne; Büchner Thomas; Hiddemann Wolfgang; Haferlach Torsten
The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups.
Haematologica 2004;89(9):1082-90.
2004: Lenz Georg; Hiddemann Wolfgang; Dreyling Martin
The role of fludarabine in the treatment of follicular and mantle cell lymphoma.
Cancer 2004;101(5):883-93.
2004: Braess Jan; Schneiderat Peter; Schoch Claudia; Fiegl Michael; Lorenz Isolde; Hiddemann Wolfgang
Functional analysis of apoptosis induction in acute myeloid leukaemia-relevance of karyotype and clinical treatment response.
British journal of haematology 2004;126(3):338-47.
2004: Krych M; Dreyling M; Kneba M; Hoelzer D; Hiddemann W; Hallek M
[Prophylaxis and differential therapy of tumorlysis syndrome]
Deutsche medizinische Wochenschrift (1946) 2004;129(25-26):1440-5.
2004: Kern Wolfgang; Haferlach Torsten; Schnittger Susanne; Hiddemann Wolfgang; Schoch Claudia
Prognosis in therapy-related acute myeloid leukemia and impact of karyotype.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(12):2510-1.
2004: Bacher U; Kern W; Schoch C; Hiddemann W; Haferlach T
Discrimination of chronic lymphocytic leukemia (CLL) and CLL/PL by cytomorphology can clearly be correlated to specific genetic markers as investigated by interphase fluorescence in situ hybridization (FISH).
Annals of hematology 2004;83(6):349-55.
2004: Büchner Thomas; Berdel Wolfgang E; Hiddemann Wolfgang
Priming with granulocyte colony-stimulating factor--relation to high-dose cytarabine in acute myeloid leukemia.
The New England journal of medicine 2004;350(21):2215-6.
2004: Kern Wolfgang; Voskova Daniela; Schoch Claudia; Schnittger Susanne; Hiddemann Wolfgang; Haferlach Torsten
Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia.
Haematologica 2004;89(5):528-40.
2004: Haferlach Torsten; Kern Wolfgang; Schoch Claudia; Schnittger Susanne; Sauerland Maria Cristina; Heinecke Achim; Büchner Thomas; Hiddemann Wolfgang;
A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group.
Haematologica 2004;89(4):408-18.
2004: Bagrintseva Ksenia; Schwab Ruth; Kohl Tobias M; Schnittger Susanne; Eichenlaub Sabine; Ellwart Joachim W; Hiddemann Wolfgang; Spiekermann Karsten
Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells.
Blood 2004;103(6):2266-75.
2004: Lenz G; Dreyling M; Hiddemann W
Mantle cell lymphoma: established therapeutic options and future directions.
Annals of hematology 2004;83(2):71-7.
2004: Rawat Vijay P S; Cusan Monica; Deshpande Aniruddha; Hiddemann Wolfgang; Quintanilla-Martinez Leticia; Humphries R Keith; Bohlander Stefan K; Feuring-Buske Michaela; Buske Christian
Ectopic expression of the homeobox gene Cdx2 is the transforming event in a mouse model of t(12;13)(p13;q12) acute myeloid leukemia.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(3):817-22.
2004: Kohlmann A; Schoch C; Schnittger S; Dugas M; Hiddemann W; Kern W; Haferlach T
Pediatric acute lymphoblastic leukemia (ALL) gene expression signatures classify an independent cohort of adult ALL patients.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2004;18(1):63-71.
2004: Schoch C; Kern W; Schnittger S; Hiddemann W; Haferlach T
Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2004;18(1):120-5.
2004: Kern Wolfgang; Voskova Daniela; Schnittger Susanne; Schoch Claudia; Hiddemann Wolfgang; Haferlach Torsten
Four-fold staining including CD45 gating improves the sensitivity of multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia.
The hematology journal : the official journal of the European Haematology Association / EHA 2004;5(5):410-8.
2004: Kern Wolfgang; Kohlmann Alexander; Schnittger Susanne; Hiddemann Wolfgang; Schoch Claudia; Haferlach Torsten
Gene expression profiling as a diagnostic tool in acute myeloid leukemia.
American journal of pharmacogenomics : genomics-related research in drug development and clinical practice 2004;4(4):225-37.
2004: Schnittger Susanne; Schoch Claudia; Kern Wolfgang; Hiddemann Wolfgang; Haferlach Torsten
FLT3 length mutations as marker for follow-up studies in acute myeloid leukaemia.
Acta haematologica 2004;112(1-2):68-78.
2004: Kienast J; Stelljes M; Berning B; Kröger M; Sauerland M C; Heinecke A; Schoch C; Wörmann B; Büchner T; Hiddemann W; Berdel W E;
Transplantation strategies in AML: AMLCG data.
Annals of hematology 2004;83 Suppl 1():S136-7.
2004: Büchner Th; Hiddemann W; Berdel W E; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig W D; Maschmeyer G; Staib P; Balleisen L; Grüneisen A; Aul C; Lengfelder E; Hehlmann R; Kern W; Serve H L; Mesters R M; Eimermacher H; Frickhofen N; Kienast J; Giagounidis A; Sauerland M C; Heinecke A;
Subgroup specific therapy effects in AML: AMLCG data.
Annals of hematology 2004;83 Suppl 1():S100-1.
2004: Buske C; Dreyling H; Unterhalt M; Hiddemann W
Novel treatment strategies in follicular lymphoma.
Annals of hematology 2004;83 Suppl 1():S72.
2004: Hiddemann W; Kern W; Heinecke A; Sauerland C; Büchner Th;
Priming with G-CSF in acute myeloid leukemia: preliminary data of the AMLCG.
Annals of hematology 2004;83 Suppl 1():S53-4.
2004: Kern W; Haferlach T; Schoch C; Sauerland M C; Heinecke A; Wörmann B; Berdel W; Büchner Th; Hiddemann W
Risk-adapted therapy of AML: the AMLCG experience.
Annals of hematology 2004;83 Suppl 1():S49-51.
2004: Hutter Grit; Nickenig Christina; Garritsen Henk; Hellenkamp Frank; Hoerning Andre; Hiddemann Wolfgang; Dreyling Martin
Use of polymorphisms in the noncoding region of the human mitochondrial genome to identify potential contamination of human leukemia-lymphoma cell lines.
The hematology journal : the official journal of the European Haematology Association / EHA 2004;5(1):61-8.
2003: Cheson Bruce D; Bennett John M; Kopecky Kenneth J; Büchner Thomas; Willman Cheryl L; Estey Elihu H; Schiffer Charles A; Doehner Hartmut; Tallman Martin S; Lister T Andrew; Lo-Coco Francesco; Willemze Roel; Biondi Andrea; Hiddemann Wolfgang; Larson Richard A; Löwenberg Bob; Sanz Miguel A; Head David R; Ohno Ryuzo; Bloomfield Clara D;
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(24):4642-9.
2003: Büchner Thomas; Hiddemann Wolfgang; Berdel Wolfgang E; Wörmann Bernhard; Schoch Claudia; Fonatsch Christa; Löffler Helmut; Haferlach Torsten; Ludwig Wolf-Dieter; Maschmeyer Georg; Staib Peter; Aul Carlo; Gruneisen Andreas; Lengfelder Eva; Frickhofen Norbert; Kern Wolfgang; Serve Hubert L; Mesters Rolf M; Sauerland Maria Cristina; Heinecke Achim;
6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(24):4496-504.
2003: Hacker Ulrich; Lenz Georg; Brehm Gerd; Müller-Höcker Josef; Schalhorn Andreas; Hiddemann Wolfgang
Metastasis of a rectal adenocarcinoma to the thyroid gland: diagnostic and therapeutic implications.
Anticancer research 2003;23(6D):4973-6.
2003: Lenz Georg; Golf Alexander; Rüdiger Thomas; Hiddemann Wolfgang; Haferlach Torsten
Epstein-Barr virus-associated B-cell non-Hodgkin lymphoma following treatment of hairy cell leukemia with cladribine.
Blood 2003;102(9):3457-8.
2003: Haferlach Torsten; Kohlmann Alexander; Kern Wolfgang; Hiddemann Wolfgang; Schnittger Susanne; Schoch Claudia
Gene expression profiling as a tool for the diagnosis of acute leukemias.
Seminars in hematology 2003;40(4):281-95.
2003: Lenz Georg; Hacker Ulrich T; Kern Wolfgang; Schalhorn Andreas; Hiddemann Wolfgang
Adverse reactions to oxaliplatin: a retrospective study of 25 patients treated in one institution.
Anti-cancer drugs 2003;14(9):731-3.
2003: Schnittger Susanne; Weisser Martin; Schoch Claudia; Hiddemann Wolfgang; Haferlach Torsten; Kern Wolfgang
New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts.
Blood 2003;102(8):2746-55.
2003: Schoch Claudia; Schnittger Susanne; Klaus Mirjam; Kern Wolfgang; Hiddemann Wolfgang; Haferlach Torsten
AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases.
Blood 2003;102(7):2395-402.
2003: Grigg Andrew; Solal-Celigny Philippe; Hoskin Peter; Taylor Kerry; McMillan Andrew; Forstpointner Roswitha; Bacon Pamela; Renwick Jennifer; Hiddemann Wolfgang;
Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma.
Leukemia & lymphoma 2003;44(9):1503-8.
2003: Kern Wolfgang; Kohlmann Alexander; Wuchter Christian; Schnittger Susanne; Schoch Claudia; Mergenthaler Susanne; Ratei Richard; Ludwig Wolf-Dieter; Hiddemann Wolfgang; Haferlach Torsten
Correlation of protein expression and gene expression in acute leukemia.
Cytometry. Part B, Clinical cytometry 2003;55(1):29-36.
2003: Elsässer Annika; Franzen Michael; Kohlmann Alexander; Weisser Martin; Schnittger Susanne; Schoch Claudia; Reddy Venkateshwar A; Burel Sebastian; Zhang Dong-Er; Ueffing Marius; Tenen Daniel G; Hiddemann Wolfgang; Behre Gerhard
The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner.
Oncogene 2003;22(36):5646-57.
2003: Fiegl Michael; Rieger Christina; Braess Jan; Haferlach Torsten; Schnittger Susanne; Schoch Claudia; Hiddemann Wolfgang; Ostermann Helmut
Isolated epidural chloroma with translocation t(15; 17) successfully treated with chemotherapy and all-trans-retinoic acid.
British journal of haematology 2003;122(4):688-9.
2003: Kohlmann Alexander; Schoch Claudia; Schnittger Susanne; Dugas Martin; Hiddemann Wolfgang; Kern Wolfgang; Haferlach Torsten
Molecular characterization of acute leukemias by use of microarray technology.
Genes, chromosomes & cancer 2003;37(4):396-405.
2003: Rangatia Janki; Vangala Rajani K; Singh Sheo M; Peer Zada Abdul A; Elsässer Annika; Kohlmann Alexander; Haferlach Torsten; Tenen Daniel G; Hiddemann Wolfgang; Behre Gerhard
Elevated c-Jun expression in acute myeloid leukemias inhibits C/EBPalpha DNA binding via leucine zipper domain interaction.
Oncogene 2003;22(30):4760-4.
2003: Klaus Mirjam; Schnittger Susanne; Haferlach Torsten; Dreyling Martin; Hiddemann Wolfgang; Schoch Claudia
Cytogenetics, fluorescence in situ hybridization, and reverse transcriptase polymerase chain reaction are necessary to clarify the various mechanisms leading to an MLL-AF10 fusion in acute myelocytic leukemia with 10;11 rearrangement.
Cancer genetics and cytogenetics 2003;144(1):36-43.
2003: Kern Wolfgang; Danhauser-Riedl Susanne; Ratei Richard; Schnittger Susanne; Schoch Claudia; Kolb Hans-Jochem; Ludwig Wolf-Dieter; Hiddemann Wolfgang; Haferlach Torsten
Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrow.
Haematologica 2003;88(6):646-53.
2003: Spiekermann Karsten; Bagrintseva Ksenia; Schwab Ruth; Schmieja Karin; Hiddemann Wolfgang
Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(6):2140-50.
2003: Hiddemann Wolfgang; Dreyling Martin
Mantle cell lymphoma: therapeutic strategies are different from CLL.
Current treatment options in oncology 2003;4(3):219-26.
2003: Zada Abdul A Peer; Singh Sheo M; Reddy Venkateshwar A; Elsässer Annika; Meisel Alexander; Haferlach Torsten; Tenen Daniel G; Hiddemann Wolfgang; Behre Gerhard
Downregulation of c-Jun expression and cell cycle regulatory molecules in acute myeloid leukemia cells upon CD44 ligation.
Oncogene 2003;22(15):2296-308.
2003: Gehrmann Mathias; Schmetzer Helga; Eissner Günther; Haferlach Torsten; Hiddemann Wolfgang; Multhoff Gabriele
Membrane-bound heat shock protein 70 (Hsp70) in acute myeloid leukemia: a tumor specific recognition structure for the cytolytic activity of autologous NK cells.
Haematologica 2003;88(4):474-6.
2003: Schoch Claudia; Schnittger Susanne; Kern Wolfgang; Dugas Martin; Hiddemann Wolfgang; Haferlach Torsten
Acute myeloid leukemia with recurring chromosome abnormalities as defined by the WHO-classification: incidence of subgroups, additional genetic abnormalities, FAB subtypes and age distribution in an unselected series of 1,897 patients with acute myeloid leukemia.
Haematologica 2003;88(3):351-2.
2003: Mueller Beatrice U; Pabst Thomas; Osato Motomi; Asou Norio; Johansen Lisa M; Minden Mark D; Behre Gerhard; Hiddemann Wolfgang; Ito Yoshiaki; Tenen Daniel G
Heterozygous PU.1 mutations are associated with acute myeloid leukemia.
Blood 2003;101(5):2074.
2003: Hiddemann Wolfgang; Dreyling Martin; Unterhalt Michael
Rituximab plus chemotherapy in follicular and mantle cell lymphomas.
Seminars in oncology 2003;30(1 Suppl 2):16-20.
2003: Delabesse Eric; Li Juan; Schnittger Susanne; Hiddemann Wolfgang; Green Anthony R
Absence of SCL mutations in myeloid malignancies.
British journal of haematology 2003;120(3):482-3.
2003: Spiekermann Karsten; Dirschinger Ralf J; Schwab Ruth; Bagrintseva Ksenia; Faber Florian; Buske Christian; Schnittger Susanne; Kelly Louise M; Gilliland D Gary; Hiddemann Wolfgang
The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3.
Blood 2003;101(4):1494-504.
2003: Haferlach Torsten; Schoch Claudia; Löffler Helmut; Gassmann Winfried; Kern Wolfgang; Schnittger Susanne; Fonatsch Christa; Ludwig Wolf-Dieter; Wuchter Christian; Schlegelberger Brigitte; Staib Peter; Reichle Albrecht; Kubica Uschi; Eimermacher Hartmut; Balleisen Leopold; Grüneisen Andreas; Haase Detlef; Aul Carlo; Karow Jochen; Lengfelder Eva; Wörmann Bernhard; Heinecke Achim; Sauerland Maria Cristina; Büchner Thomas; Hiddemann Wolfgang
Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(2):256-65.
2003: Kern Wolfgang; Haferlach Torsten; Schoch Claudia; Loffler Helmut; Gassmann Winfried; Heinecke Achim; Sauerland Maria Christina; Berdel Wolfgang; Buchner Thomas; Hiddemann Wolfgang
Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial.
Blood 2003;101(1):64-70.
2003: Vangala Rajani K; Heiss-Neumann Marion S; Rangatia Janki S; Singh Sheo M; Schoch Claudia; Tenen Daniel G; Hiddemann Wolfgang; Behre Gerhard
The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia.
Blood 2003;101(1):270-7.
2002: Rangatia Janki; Vangala Rajani Kanth; Treiber Nicolai; Zhang Pu; Radomska Hanna; Tenen Daniel G; Hiddemann Wolfgang; Behre Gerhard
Downregulation of c-Jun expression by transcription factor C/EBPalpha is critical for granulocytic lineage commitment.
Molecular and cellular biology 2002;22(24):8681-94.
2002: Spiekermann Karsten; Bagrintseva Ksenia; Schoch Claudia; Haferlach Torsten; Hiddemann Wolfgang; Schnittger Susanne
A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia.
Blood 2002;100(9):3423-5.
2002: Feuring-Buske M; Hiddemann W; Buske C
[Pathogenesis and biology of leukemias]
Der Internist 2002;43(10):1179-89.
2002: Hiddemann W
[Clinical studies: an endangered element in optimizing treatment]
Deutsche medizinische Wochenschrift (1946) 2002;127(42):2185.
2002: Forstpointner R; Hänel A; Repp R; Hermann S; Metzner B; Pott C; Hartmann F; Rothmann F; Böck H P; Wandt H; Unterhalt M; Hiddemann W
[Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group]
Deutsche medizinische Wochenschrift (1946) 2002;127(43):2253-8.
2002: Kern W; Haferlach T; Schnittger S; Ludwig W D; Hiddemann W; Schoch C
Karyotype instability between diagnosis and relapse in 117 patients with acute myeloid leukemia: implications for resistance against therapy.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2002;16(10):2084-91.
2002: Kern Wolfgang; Braess Jan; Kotschofsky Marion; Samel Stefan; Becker Heinz; Hiddemann Wolfgang; Schleyer Eberhard
Application of cisplatin as intraoperative hyperthermic peritoneal lavage (IHPL) in patients with locally advanced gastric cancer: analysis of pharmacokinetics and of nephrotoxicity.
Anticancer research 2002;22(5):3099-102.
2002: Schoch Claudia; Haferlach Torsten; Bursch Sabina; Gerstner Daniela; Schnittger Susanne; Dugas Martin; Kern Wolfgang; Löffler Helmut; Hiddemann Wolfgang
Loss of genetic material is more common than gain in acute myeloid leukemia with complex aberrant karyotype: a detailed analysis of 125 cases using conventional chromosome analysis and fluorescence in situ hybridization including 24-color FISH.
Genes, chromosomes & cancer 2002;35(1):20-9.
2002: Buhmann Raymund; Kurzeder Christian; Rehklau Jutta; Westhaus Doreen; Bursch Sabina; Hiddemann Wolfgang; Haferlach Torsten; Hallek Michael; Schoch Claudia
CD40L stimulation enhances the ability of conventional metaphase cytogenetics to detect chromosome aberrations in B-cell chronic lymphocytic leukaemia cells.
British journal of haematology 2002;118(4):968-75.
2002: Wendtner Clemens-Martin; Kofler David M; Theiss Hans D; Kurzeder Christian; Buhmann Raymund; Schweighofer Carmen; Perabo Luca; Danhauser-Riedl Susanne; Baumert Jens; Hiddemann Wolfgang; Hallek Michael; Büning Hildegard
Efficient gene transfer of CD40 ligand into primary B-CLL cells using recombinant adeno-associated virus (rAAV) vectors.
Blood 2002;100(5):1655-61.
2002: Nickenig C; Schürmann M; Waggershauser T; Tympner C; Grabein B; Hiddemann W
[41-year-old patient after liver transplantation with acute abdominal pain]
Der Internist 2002;43(8):995-8.
2002: Behre Gerhard; Reddy Venkateshwar A; Tenen Daniel G; Hiddemann Wolfgang; Zada Abdul A Peer; Singh Sheo M
Proteomic analysis of transcription factor interactions in myeloid stem cell development and leukaemia.
Expert opinion on therapeutic targets 2002;6(4):491-5.
2002: Haferlach Torsten; Schoch Claudia; Schnittger Susanne; Kern Wolfgang; Löffler Helmut; Hiddemann Wolfgang
Distinct genetic patterns can be identified in acute monoblastic and acute monocytic leukaemia (FAB AML M5a and M5b): a study of 124 patients.
British journal of haematology 2002;118(2):426-31.
2002: Mueller Beatrice U; Pabst Thomas; Osato Motomi; Asou Norio; Johansen Lisa M; Minden Mark D; Behre Gerhard; Hiddemann Wolfgang; Ito Yoshiaki; Tenen Daniel G
Heterozygous PU.1 mutations are associated with acute myeloid leukemia.
Blood 2002;100(3):998-1007.
2002: Spiekermann Karsten; Faber Florian; Voswinckel Robert; Hiddemann Wolfgang
The protein tyrosine kinase inhibitor SU5614 inhibits VEGF-induced endothelial cell sprouting and induces growth arrest and apoptosis by inhibition of c-kit in AML cells.
Experimental hematology 2002;30(7):767-73.
2002: Wendtner Clemens-M; Abdel-Rahman Sultan; Krych Matthäus; Baumert Jens; Lindner Lars H; Baur Andrea; Hiddemann Wolfgang; Issels Rolf D
Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(14):3156-64.
2002: Schoch Claudia; Kohlmann Alexander; Schnittger Susanne; Brors Benedikt; Dugas Martin; Mergenthaler Susanne; Kern Wolfgang; Hiddemann Wolfgang; Eils Roland; Haferlach Torsten
Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(15):10008-13.
2002: Reddy Venkateshwar A; Iwama Atsushi; Iotzova Guergana; Schulz Mathias; Elsasser Annika; Vangala Rajani K; Tenen Daniel G; Hiddemann Wolfgang; Behre Gerhard
Granulocyte inducer C/EBPalpha inactivates the myeloid master regulator PU.1: possible role in lineage commitment decisions.
Blood 2002;100(2):483-90.
2002: Schnittger Susanne; Schoch Claudia; Dugas Martin; Kern Wolfgang; Staib Peter; Wuchter Christian; Löffler Helmut; Sauerland Cristina Maria; Serve Hubert; Büchner Thomas; Haferlach Torsten; Hiddemann Wolfgang
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.
Blood 2002;100(1):59-66.
2002: Behre Gerhard; Singh Sheo M; Liu Huaitian; Bortolin Laura T; Christopeit Max; Radomska Hanna S; Rangatia Janki; Hiddemann Wolfgang; Friedman Alan D; Tenen Daniel G
Ras signaling enhances the activity of C/EBP alpha to induce granulocytic differentiation by phosphorylation of serine 248.
The Journal of biological chemistry 2002;277(29):26293-9.
2002: Schmitt Barbara; Wendtner Clemens M; Bergmann Manuela; Busch Raymonde; Franke Astrid; Pasold Rita; Schlag Rudolf; Hopfinger Georg; Hiddemann Wolfgang; Emmerich Bertold; Hallek Michael
Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia.
Clinical lymphoma 2002;3(1):26-35.
2002: Bäsecke J; Feuring-Buske M; Brittinger G; Schaefer U W; Hiddemann W; Griesinger F
Transcription of AML1 in hematopoietic subfractions of normal adults.
Annals of hematology 2002;81(5):254-7.
2002: Hollburg Wiebke; Hiddemann Wolfgang
[30. Splenomegaly: a symptom with many etiologies]
MMW Fortschritte der Medizin 2002;144(14):I-XII; quiz XIII-XIV.
2002: Salih Helmut R; Starling Gary C; Brandl Stephan F; Pelka-Fleischer Renate; Haferlach Torsten; Hiddemann Wolfgang; Kiener Peter A; Nuessler Volkmar
Differentiation of promyelocytic leukaemia: alterations in Fas (CD95/Apo-1) and Fas ligand (CD178) expression.
British journal of haematology 2002;117(1):76-85.
2002: Büchner Thomas; Hiddemann Wolfgang; Berdel Wolfgang; Wörmann Bernhard; Schoch Claudia; Löffler Helmut; Haferlach Torsten; Schumacher Andrea; Staib Peter; Balleisen Leopold; Grüneisen Andreas; Rasche Herbert; Aul Carlo; Heyll Axel; Lengfelder Eva; Ludwig Wolf-Dieter; Maschmeyer Georg; Eimermacher Hartmut; Karow Jochen; Frickhofen Norbert; Hirschmann Wolf-Dietrich; Sauerland Maria-Cristina;
Acute myeloid leukemia: treatment over 60.
Reviews in clinical and experimental hematology 2002;6(1):46-59; discussion 86-7.
2002: Heinemann V; Hiddemann W
[Current treatment strategies in breast carcinoma]
Der Internist 2002;43(3):327-8.
2002: Spiekermann Karsten; Pau Michael; Schwab Ruth; Schmieja Karin; Franzrahe Sabine; Hiddemann Wolfgang
Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor cells.
Experimental hematology 2002;30(3):262-71.
2002: Stoetzer Oliver J; Pogrebniak Alexei; Pelka-Fleischer Renate; Hasmann Max; Hiddemann Wolfgang; Nuessler Volkmar
Modulation of apoptosis by mitochondrial uncouplers: apoptosis-delaying features despite intrinsic cytotoxicity.
Biochemical pharmacology 2002;63(3):471-83.
2002: Schoch C; Schnittger S; Bursch S; Gerstner D; Hochhaus A; Berger U; Hehlmann R; Hiddemann W; Haferlach T
Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2002;16(1):53-9.
2002: Schoch Claudia; Schnittger Susanne; Kern Wolfgang; Lengfelder Eva; Löffler Helmut; Hiddemann Wolfgang; Haferlach Torsten
Rapid diagnostic approach to PML-RARalpha-positive acute promyelocytic leukemia.
The hematology journal : the official journal of the European Haematology Association / EHA 2002;3(5):259-63.
2001: Schleuning M; Hiddemann W
[New molecular therapy options in hematology and oncology, exemplified by STI571]
Der Internist 2001;42(12):1591-7.
2001: Dugas M; Schoch C; Schnittger S; Haferlach T; Danhauser-Riedl S; Hiddemann W; Messerer D; Uberla K
A comprehensive leukemia database: integration of cytogenetics, molecular genetics and microarray data with clinical information, cytomorphology and immunophenotyping.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2001;15(12):1805-10.
2001: Nickenig C; Lang N K; Schoch C; Hiddemann W; Haferlach T
New insights into the biology of multiple myeloma using a combination of May-Grünwald-Giemsa staining and fluorescence in situ hybridization techniques at the single cell level.
Annals of hematology 2001;80(11):662-8.
2001: Multhoff G; Pfister K; Gehrmann M; Hantschel M; Gross C; Hafner M; Hiddemann W
A 14-mer Hsp70 peptide stimulates natural killer (NK) cell activity.
Cell stress & chaperones 2001;6(4):337-44.
2001: Stemmler H J; Gutschow K; Sommer H; Malekmohammadi M; Kentenich C H; Forstpointner R; Geuenich S; Bischoff J; Hiddemann W; Heinemann V
Weekly docetaxel (Taxotere) in patients with metastatic breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(10):1393-8.
2001: Stötzer O J; Schleuning M; Ledderose G; Hiddemann W; Kolb H J
[Allogeneic transplantation in malignant lymphoma]
Deutsche medizinische Wochenschrift (1946) 2001;126(39):1062-9.
2001: Koch P; del Valle F; Berdel W E; Willich N A; Reers B; Hiddemann W; Grothaus-Pinke B; Reinartz G; Brockmann J; Temmesfeld A; Schmitz R; Rübe C; Probst A; Jaenke G; Bodenstein H; Junker A; Pott C; Schultze J; Heinecke A; Parwaresch R; Tiemann M;
Primary gastrointestinal non-Hodgkin's lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma--results of the prospective German Multicenter Study GIT NHL 01/92.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(18):3874-83.
2001: Koch P; del Valle F; Berdel W E; Willich N A; Reers B; Hiddemann W; Grothaus-Pinke B; Reinartz G; Brockmann J; Temmesfeld A; Schmitz R; Rübe C; Probst A; Jaenke G; Bodenstein H; Junker A; Pott C; Schultze J; Heinecke A; Parwaresch R; Tiemann M;
Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(18):3861-73.
2001: Wendtner C; Abdel-Rahman S; Baumert J; Falk M H; Krych M; Santl M; Hiddemann W; Issels R D
Treatment of primary, recurrent or inadequately resected high-risk soft-tissue sarcomas (STS) of adults: results of a phase II pilot study (RHT-95) of neoadjuvant chemotherapy combined with regional hyperthermia.
European journal of cancer (Oxford, England : 1990) 2001;37(13):1609-16.
2001: Issels R D; Abdel-Rahman S; Wendtner C; Falk M H; Kurze V; Sauer H; Aydemir U; Hiddemann W
Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent high-risk adult soft-tissue sarcomas (STS) of adults: long-term results of a phase II study.
European journal of cancer (Oxford, England : 1990) 2001;37(13):1599-608.
2001: Büchner T; Hiddemann W; Berdel W; Wörmann B; Löffler H; Schoch C; Haferlach T; Ludwig W D; Maschmeyer G; Staib P; Andreesen R; Balleisen L; Haase D; Eimermacher H; Aul C; Rasche H; Uhlig J; Grüneisen A; Reis H E; Hartlapp J; Hirschmann W D; Weh H J; Pielken H J; Gassmann W; Sauerland M C; Heinecke A
Remission induction therapy: the more intensive the better?
Cancer chemotherapy and pharmacology 2001;48 Suppl 1():S41-4.
2001: Lang N K; Schalhorn A; Hiddemann W
[Pronounced osteoporosis, shrunken stature and blue coloration of sclerae in a 47-year old patient]
Der Internist 2001;42(8):1151-5.
2001: Hallek M; Schmitt B; Wilhelm M; Busch R; Kröber A; Fostitsch H P; Sezer O; Herold M; Knauf W; Wendtner C M; Kuse R; Freund M; Franke A; Schriever F; Nerl C; Döhner H; Thiel E; Hiddemann W; Brittinger G; Emmerich B;
Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group.
British journal of haematology 2001;114(2):342-8.
2001: Braess J; Hiddemann W
The widening role of statins: RAS signal transduction and drug-induced cytotoxicity in human leukemia: a commentary to 'interaction of cytosine arabinoside and lovastatin in human leukemia cells'.
Leukemia research 2001;25(8):661-3.
2001: Kern W; Schleyer E; Braess J; Wittmer E; Ohnesorge J; Unterhalt M; Wörmann B; Büchner T; Hiddemann W
Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone (FIS-HAM) salvage therapy in highly resistant acute leukemias.
Annals of hematology 2001;80(6):334-9.
2001: Braess J; Jahns-Streubel G; Schoch C; Haase D; Haferlach T; Fiegl M; Voss S; Kern W; Schleyer E; Hiddemann W
Proliferative activity of leukaemic blasts and cytosine arabinoside pharmacodynamics are associated with cytogenetically defined prognostic subgroups in acute myeloid leukaemia.
British journal of haematology 2001;113(4):975-82.
2001: Kern W; Beckert B; Lang N; Stemmler J; Beykirch M; Stein J; Goecke E; Waggershauser T; Braess J; Schalhorn A; Hiddemann W
Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(5):599-603.
2001: Schoch C; Bursch S; Kern W; Schnittger S; Hiddemann W; Haferlach T
Gain of an isochromosome 5p: a new recurrent chromosome abnormality in acute monoblastic leukemia.
Cancer genetics and cytogenetics 2001;127(1):85-8.
2001: Gerl A; Mühlbayer D; Hansmann G; Mraz W; Hiddemann W
The impact of chemotherapy on Leydig cell function in long term survivors of germ cell tumors.
Cancer 2001;91(7):1297-303.
2001: Pabst T; Mueller B U; Harakawa N; Schoch C; Haferlach T; Behre G; Hiddemann W; Zhang D E; Tenen D G
AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.
Nature medicine 2001;7(4):444-51.
2001: Pabst T; Mueller B U; Zhang P; Radomska H S; Narravula S; Schnittger S; Behre G; Hiddemann W; Tenen D G
Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia.
Nature genetics 2001;27(3):263-70.
2001: Jahns-Streubel G; Braess J; Schoch C; Fonatsch C; Haase D; Binder C; Wörmann B; Büchner T; Hiddemann W
Cytogenetic subgroups in acute myeloid leukemia differ in proliferative activity and response to GM-CSF.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2001;15(3):377-84.
2001: Kern W; Braess J; Friedrichsen S; Kaufmann C C; Schleyer E; Hiddemann W
Carboplatin pharmacokinetics in patients receiving carboplatin and paclitaxel/docetaxel for advanced lung cancers: impact of age and renal function on area under the curve.
Journal of cancer research and clinical oncology 2001;127(1):64-8.
2001: Schoch C; Haferlach T; Haase D; Fonatsch C; Löffler H; Schlegelberger B; Staib P; Sauerland M C; Heinecke A; Büchner T; Hiddemann W;
Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients.
British journal of haematology 2001;112(1):118-26.
2001: Willich N A; Reinartz G; Reers B; Hiddemann W; Tiemann M; Parwaresch R; Grothaus-Pinke B; Kocik J; Koch P;
Radiotherapy in early stage gastrointestinal lymphoma: results of the German GIT-NHL group.
Annals of hematology 2001;80 Suppl 3():B97-9.
2000: Multhoff G; Pfister K; Botzler C; Jordan A; Scholz R; Schmetzer H; Burgstahler R; Hiddemann W
Adoptive transfer of human natural killer cells in mice with severe combined immunodeficiency inhibits growth of Hsp70-expressing tumors.
International journal of cancer. Journal international du cancer 2000;88(5):791-7.
2000: Kern W; Beckert B; Lang N; Waggershauser T; Braess J; Schalhorn A; Hiddemann W
Hepatic arterial infusion with oxaliplatin, folinic acid, and 5-fluorouracil in patients with hepatic metastases from colorectal cancer: role of carcino-embryonic antigen in assessment of response.
Anticancer research 2000;20(6D):4973-5.
2000: Hantschel M; Pfister K; Jordan A; Scholz R; Andreesen R; Schmitz G; Schmetzer H; Hiddemann W; Multhoff G
Hsp70 plasma membrane expression on primary tumor biopsy material and bone marrow of leukemic patients.
Cell stress & chaperones 2000;5(5):438-42.
2000: Maeck L; Kohaus P; Haase D; Hiddemann W; Alves F
Differential cellular expression of the human MSH2 protein in normal and myelodysplastic haematopoiesis.
British journal of haematology 2000;111(2):650-5.
2000: Büchner T; Hiddemann W; Wörmann B; Löffler H; Ludwig W D; Schoch C; Haferlach T; Maschmeyer G; Staib P; Aul C; Heyll G A; Grüneisen A; Rasche H; Eimermacher J H; Balleisen L; Pielken H J; Reis H E; Griesinger F; Reichle A; Sauerland M C; Heinecke A;
Acute myeloid leukemia in adults: is postconsolidation maintenance therapy necessary?
International journal of hematology 2000;72(3):285-9.
2000: Duell T; Mittermüller J; Hiddemann W
[Unclear lactate acidosis in a patient with heart failure under long-term diuretic therapy]
Deutsche medizinische Wochenschrift (1946) 2000;125(41):1232-4.
2000: Mahlknecht U; Schnittger S; Ottmann O G; Schoch C; Mosebach M; Hiddemann W; Hoelzer D
Chromosomal organization and localization of the human histone deacetylase 5 gene (HDAC5).
Biochimica et biophysica acta 2000;1493(3):342-8.
2000: Kern W; Braess J; Kaufmann C C; Wilde S; Schleyer E; Hiddemann W
Microalbuminuria during cisplatin therapy: relation with pharmacokinetics and implications for nephroprotection.
Anticancer research 2000;20(5C):3679-88.
2000: Feuring-Buske M; Kneba M; Unterhalt M; Engert A; Gramatzki M; Hiller E; Trümper L; Brugger W; Ostermann H; Atzpodien J; Hallek M; Aulitzky E; Hiddemann W
IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group.
Annals of hematology 2000;79(9):493-500.
2000: Lengfelder E; Reichert A; Schoch C; Haase D; Haferlach T; Löffler H; Staib P; Heyll A; Seifarth W; Saussele S; Fonatsch C; Gassmann W; Ludwig W D; Hochhaus A; Beelen D; Aul C; Sauerland M C; Heinecke A; Hehlmann R; Wörmann B; Hiddemann W; Büchner T
Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2000;14(8):1362-70.
2000: Braess J; Voss S; Jahns-Streubel G; Schoch C; Haferlach T; Kern W; Keye S; Schleyer E; Hiddemann W
The pharmacodynamic basis for the increased antileukaemic efficacy of cytosine arabinoside-based treatment regimens in acute myeloid leukaemia with a high proliferative activity.
British journal of haematology 2000;110(1):170-9.
2000: Gruber U; Vollmer T; Hiddemann W
[Palliative psychooncology--demand and methods. Beginning anew at the end?]
Der Internist 2000;41(7):619-26.
2000: Maeck L; Haase D; Schoch C; Hiddemann W; Alves F
Genetic instability in myelodysplastic syndrome: detection of microsatellite instability and loss of heterozygosity in bone marrow samples with karyotype alterations.
British journal of haematology 2000;109(4):842-6.
2000: Heinemann V; Hiddemann W
[Age factors in cancer therapy]
Der Internist 2000;41(6):544-52.
2000: Schrappe M; Reiter A; Ludwig W D; Harbott J; Zimmermann M; Hiddemann W; Niemeyer C; Henze G; Feldges A; Zintl F; Kornhuber B; Ritter J; Welte K; Gadner H; Riehm H
Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group.
Blood 2000;95(11):3310-22.
2000: Braess J; Wegendt C; Jahns-Streubel G; Kern W; Keye S; Unterhalt M; Schleyer E; Hiddemann W
Successful modulation of high-dose cytosine arabinoside metabolism in acute myeloid leukaemia by haematopoietic growth factors: no effect of ribonucleotide reductase inhibitors fludarabine and gemcitabine.
British journal of haematology 2000;109(2):388-95.
2000: Schnittger S; Kinkelin U; Schoch C; Heinecke A; Haase D; Haferlach T; Büchner T; Wörmann B; Hiddemann W; Griesinger F
Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2000;14(5):796-804.
2000: Feuring-Buske M; Buske C; Unterhalt M; Hiddemann W
Recent advances in antigen-targeted therapy in non-Hodgkin's lymphoma.
Annals of hematology 2000;79(4):167-74.
2000: Gerl A; Sauer H; Liedl B; Hiddemann W
[The therapy of testicular tumors 2 decades after the introduction of cisplatin]
Deutsche medizinische Wochenschrift (1946) 2000;125(11):327-34.
2000: Gahn B; Brittinger G; Dölken G; Döhner H; Emmerich B; Franke A; Freund M; Huber C; Kuse R; Scholten T; Hiddemann W
Multicenter phase II study of oral idarubicin in treated and untreated patients with B-chronic lymphocytic leukemia.
Leukemia & lymphoma 2000;37(1-2):169-73.
2000: Willich N A; Reinartz G; Horst E J; Delker G; Reers B; Hiddemann W; Tiemann M; Parwaresch R; Grothaus-Pinke B; Kocik J; Koch P
Operative and conservative management of primary gastric lymphoma: interim results of a German multicenter study.
International journal of radiation oncology, biology, physics 2000;46(4):895-901.
2000: Kern W; Schoch C; Haferlach T; Braess J; Unterhalt M; Wörmann B; Büchner T; Hiddemann W
Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2000;14(2):226-31.
2000: Bohlander S K; Muschinsky V; Schrader K; Siebert R; Schlegelberger B; Harder L; Schemmel V; Fonatsch C; Ludwig W D; Hiddemann W; Dreyling M H
Molecular analysis of the CALM/AF10 fusion: identical rearrangements in acute myeloid leukemia, acute lymphoblastic leukemia and malignant lymphoma patients.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2000;14(1):93-9.
1999: Hiddemann W
[Oncology. The path to a pathogenesis-oriented treatment]
Deutsche medizinische Wochenschrift (1946) 1999;124(51-52):1562-5.
1999: Beyer-Sehlmeyer G; Hiddemann W; Wörmann B; Bertram J
Suppressive subtractive hybridisation reveals differential expression of serglycin, sorcin, bone marrow proteoglycan and prostate-tumour-inducing gene I (PTI-1) in drug-resistant and sensitive tumour cell lines of haematopoetic origin.
European journal of cancer (Oxford, England : 1990) 1999;35(12):1735-42.
1999: Buske C; Hannig H; Schneider E M; Blaschke S; Hunsmann G; Bodemer W; Hiddemann W
Transforming growth factor beta is a growth-inhibitory cytokine of B cell lymphoma in SIV-infected macaques.
AIDS research and human retroviruses 1999;15(16):1477-85.
1999: Hiddemann W; Kern W; Schoch C; Fonatsch C; Heinecke A; Wörmann B; Büchner T
Management of acute myeloid leukemia in elderly patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(11):3569-76.
1999: Behr T M; Wörmann B; Gramatzki M; Riggert J; Gratz S; Béhé M; Griesinger F; Sharkey R M; Kolb H J; Hiddemann W; Goldenberg D M; Becker W
Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10 Suppl):3304s-3314s.
1999: Behr T M; Salib A L; Liersch T; Béhé M; Angerstein C; Blumenthal R D; Fayyazi A; Sharkey R M; Ringe B; Becker H; Wörmann B; Hiddemann W; Goldenberg D M; Becker W
Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10 Suppl):3232s-3242s.
1999: Peller M; Löffler R; Baur A; Turner P; Abdel-Rahman S; Futschik G; Santl M; Hiddemann W; Reiser M; Issels R
[MRI-controlled regional hyperthermia]
Der Radiologe 1999;39(9):756-63.
1999: Kern W; Schoch C; Fonatsch C; Heinecke A; Wörmann B; Büchner T; Hiddemann W
[The therapy of acute myeloid leukemia in patients of advanced age]
Deutsche medizinische Wochenschrift (1946) 1999;124(34-35):1005-14.
1999: Behr T M; Memtsoudis S; Vougioukas V; Liersch T; Gratz S; Schmidt F; Lorf T; Post S; Wörmann B; Hiddemann W; Ringe B; Becker W
Radioimmunotherapy of colorectal cancer in small volume disease and in an adjuvant setting: preclinical evaluation in comparison to equitoxic chemotherapy and initial results of an ongoing phase-I/II clinical trial.
Anticancer research 1999;19(4A):2427-32.
1999: Buske C; Feuring-Buske M; Unterhalt M; Hiddemann W
[New developments in therapy of non-Hodgkin lymphomas with monoclonal antibodies]
Deutsche medizinische Wochenschrift (1946) 1999;124(27):842-7.
1999: Karthaus M; Buchheidt D; Hiddemann W; Donnelly J P; Krcmery V; Schiel X; Wilhelm M; Helmerking M
European Surveillance of Infections in Cancer Patients--ESIC.
Chemotherapy 1999;45(4):237-41.
1999: Gahn B; Wendenburg B; Troff C; Neef J; Grove D; Haferlach T; Hiddemann W; Wörmann B
Analysis of progenitor cell involvement in B-CLL by simultaneous immunophenotypic and genotypic analysis at the single cell level.
British journal of haematology 1999;105(4):955-9.
1999: Büchner T; Hiddemann W; Wörmann B; Löffler H; Gassmann W; Haferlach T; Fonatsch C; Haase D; Schoch C; Hossfeld D; Lengfelder E; Aul C; Heyll A; Maschmeyer G; Ludwig W D; Sauerland M C; Heinecke A
Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group.
Blood 1999;93(12):4116-24.
1999: Schwartz S; Behre G; Heinemann V; Wandt H; Schilling E; Arning M; Trittin A; Kern W V; Boenisch O; Bosse D; Lenz K; Ludwig W D; Hiddemann W; Siegert W; Beyer J
Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial.
Blood 1999;93(11):3654-61.
1999: Binder C; Schulz M; Hiddemann W; Oellerich M
Caspase-activation and induction of inducible nitric oxide-synthase during TNF alpha-triggered apoptosis.
Anticancer research 1999;19(3A):1715-20.
1999: Biethahn S; Alves F; Wilde S; Hiddemann W; Spiekermann K
Expression of granulocyte colony-stimulating factor- and granulocyte-macrophage colony-stimulating factor-associated signal transduction proteins of the JAK/STAT pathway in normal granulopoiesis and in blast cells of acute myelogenous leukemia.
Experimental hematology 1999;27(5):885-94.
1999: Braess J; Wegendt C; Feuring-Buske M; Riggert J; Kern W; Hiddemann W; Schleyer E
Leukaemic blasts differ from normal bone marrow mononuclear cells and CD34+ haemopoietic stem cells in their metabolism of cytosine arabinoside.
British journal of haematology 1999;105(2):388-93.
1999: Buske C; Feuring-Buske M; Unterhalt M; Hiddemann W
Monoclonal antibody therapy for B cell non-Hodgkin's lymphomas: emerging concepts of a tumour-targeted strategy.
European journal of cancer (Oxford, England : 1990) 1999;35(4):549-57.
1999: Griesinger F; Pirò-Noack M; Kaib N; Falk M; Renziehausen A; Troff C; Grove D; Schnittger S; Büchner T; Ritter J; Hiddemann W; Wörmann B
Leukaemia-associated immunophenotypes (LAIP) are observed in 90% of adult and childhood acute lymphoblastic leukaemia: detection in remission marrow predicts outcome.
British journal of haematology 1999;105(1):241-55.
1999: Kern W; Braess J; Böttger B; Kaufmann C C; Hiddemann W; Schleyer E
Oxaliplatin pharmacokinetics during a four-hour infusion.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(4):761-5.
1999: Gökbuget N; Arnold R; Büchner T; Freund M; Gassmann W; Heil G; Hiddemann W; Löffler H; Lipp T; Ludwig W D; Maschmeyer G; Thiel E; Messerer D; Hoelzer D
[Treatment of adult acute lymphoblastic leukemia]
Praxis 1999;88(10):407-20.
1999: Feuring-Buske M; Haase D; Buske C; Hiddemann W; Wörmann B
Clonal chromosomal abnormalities in the stem cell compartment of patients with acute myeloid leukemia in morphological complete remission.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1999;13(3):386-92.
1999: Buchheidt D; Hiddemann W; Schiel X; Kremery V; Karthaus M; Donnelly J P; Wilhelm M; Maschmeyer G; Link H; Adam D; Helmerking M
European surveillance of infections and risk factors in cancer patients.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1999;18(2):161-3.
1999: Wulf G G; Unterhalt M; Buchwald A; Zenker D; Kreuzer H; Hiddemann W
Hypercoagulability in a patient with hypodysfibrinogenemia: implications for clinical management.
Acta haematologica 1999;101(4):209-12.
1999: Verbeek W; Wörmann B; Koch P; Aul C; Hinrichs H F; Balleisen L; Rowe J M; Bennett J; Haase D; Fonatsch C; Heinecke A; Büchner T; Hiddemann W
Results of a randomized double-blind placebo-controlled trial evaluating sequential high-dose cytosine arabinoside/mitoxantrone chemotherapy with or without granulocyte/macrophage-colony-stimulating factor in high-risk myelodysplastic syndromes.
Journal of cancer research and clinical oncology 1999;125(6):369-74.
1998: Buske C; Engert A; Schnell R; Diehl V; Hiddemann W
[Monoclonal antibodies in therapy of malignant lymphomas]
Der Internist 1998;39(12):1205-14.
1998: Buske C; Becker D; Feuring-Buske M; Hannig H; Griesinger F; Hiddemann W; Wörmann B
TGF-beta and its receptor complex in leukemic B-cell precursors.
Experimental hematology 1998;26(12):1155-61.
1998: Haferlach T; Löffler H; Nickenig C; Ramm-Petersen L; Meeder M; Schoch R; Schlegelberger B; Schnittger S; Schoch C; Hiddemann W
Cell lineage specific involvement in acute promyelocytic leukaemia (APL) using a combination of May-Grünwald-Giemsa staining and fluorescence in situ hybridization techniques for the detection of the translocation t(15;17)(q22;q12).
British journal of haematology 1998;103(1):93-9.
1998: Wulf G G; Reichard U; Wormann B; Hiddemann W
Pneumocystis carinii pneumonia with peripheral nodular infiltrates in a patient with T-acute lymphoblastic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(10):3476-7.
1998: Pott C; Tiemann M; Linke B; Ott M M; von Hofen M; Bolz I; Hiddemann W; Parwaresch R; Kneba M
Structure of Bcl-1 and IgH-CDR3 rearrangements as clonal markers in mantle cell lymphomas.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1998;12(10):1630-7.
1998: Braess J; Freund M; Hanauske A; Heil G; Kaufmann C; Kern W; Schüssler M; Hiddemann W; Schleyer E
Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma--phase I/II studies and pharmacokinetics.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1998;12(10):1618-26.
1998: Kern W; Braess J; Grote-Metke A; Kuse H; Fuchs R; Hossfeld D K; Reichle A; Wörmann B; Büchner T; Hiddemann W
Combination of aclarubicin and etoposide for the treatment of advanced acute myeloid leukemia: results of a prospective multicenter phase II trial. German AML Cooperative Group.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1998;12(10):1522-6.
1998: Kern W; Aul C; Maschmeyer G; Kuse R; Kerkhoff A; Grote-Metke A; Eimermacher H; Kubica U; Wörmann B; Büchner T; Hiddemann W
Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy for refractory and relapsed acute myeloid leukemia. German AML Cooperative Group.
Annals of hematology 1998;77(3):115-22.
1998: Schnittger S; Wörmann B; Hiddemann W; Griesinger F
Partial tandem duplications of the MLL gene are detectable in peripheral blood and bone marrow of nearly all healthy donors.
Blood 1998;92(5):1728-34.
1998: Hannig H; Buske C; Mätz-Rensing K; Hunsmann G; Hiddemann W; Bodemer W
Elevated serum level of soluble CD23 precedes development of B-non-Hodgkin's lymphoma in SIV-infected Rhesus monkeys.
International journal of cancer. Journal international du cancer 1998;77(5):734-40.
1998: Hiddemann W; Griesinger F; Unterhalt M
Interferon alfa for the treatment of follicular lymphomas.
The cancer journal from Scientific American 1998;4 Suppl 2():S13-8.
1998: Kern W; Behre G; Rudolf T; Kerkhoff A; Grote-Metke A; Eimermacher H; Kubica U; Wörmann B; Büchner T; Hiddemann W
Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study. German AML Cooperative Group.
Cancer 1998;83(2):291-301.
1998: Kern W; Aul C; Maschmeyer G; Schönrock-Nabulsi R; Ludwig W D; Bartholomäus A; Bettelheim P; Wörmann B; Büchner T; Hiddemann W
Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1998;12(7):1049-55.
1998: Wulf G G; Jahns-Streubel G; Hemmerlein B; Bonnekessen K; Wörmann B; Hiddemann W
Plasmacytosis in acute myeloid leukemia: two cases of plasmacytosis and increased IL-6 production in the AML blast cells.
Annals of hematology 1998;76(6):273-7.
1998: Wörmann B; Buske C; Hiddemann W
[Systemic therapy of low malignancy non-Hodgkin lymphomas]
Praxis 1998;87(23):806-11.
1998: Dreyling M H; Schrader K; Fonatsch C; Schlegelberger B; Haase D; Schoch C; Ludwig W; Löffler H; Büchner T; Wörmann B; Hiddemann W; Bohlander S K
MLL and CALM are fused to AF10 in morphologically distinct subsets of acute leukemia with translocation t(10;11): both rearrangements are associated with a poor prognosis.
Blood 1998;91(12):4662-7.
1998: Hiddemann W; Jahns-Streubel G; Verbeek W; Wörmann B; Haase D; Schoch C
Intensive therapy for high-risk myelodysplastic syndromes and the biological significance of karyotype abnormalities.
Leukemia research 1998;22 Suppl 1():S23-6.
1998: Wörmann B; Meden H; Riggert J; Humpe A; Wulf G; Koch B; Köhler M; Kuhn W; Hiddemann W
Early intensive and myeloablative adjuvant chemotherapy in women with high-risk breast cancer.
Anticancer research 1998;18(3C):2237-41.
1998: Hiddemann W; Unterhalt M; Herrmann R; Wöltjen H H; Kreuser E D; Trümper L; Reuss-Borst M; Terhardt-Kasten E; Busch M; Neubauer A; Kaiser U; Hanrath R D; Middeke H; Helm G; Freund M; Stein H; Tiemann M; Parwaresch R
Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(5):1922-30.
1998: Bertram J; Palfner K; Hiddemann W; Kneba M
Overexpression of ribosomal proteins L4 and L5 and the putative alternative elongation factor PTI-1 in the doxorubicin resistant human colon cancer cell line LoVoDxR.
European journal of cancer (Oxford, England : 1990) 1998;34(5):731-6.
1998: Bertram J; Palfner K; Hiddemann W; Kneba M
Elevated expression of S100P, CAPL and MAGE 3 in doxorubicin-resistant cell lines: comparison of mRNA differential display reverse transcription-polymerase chain reaction and subtractive suppressive hybridization for the analysis of differential gene expression.
Anti-cancer drugs 1998;9(4):311-7.
1998: Kern W; Braess J; Bertz H; Pott C; Schleyer E; Finke J; Rüchel R; Hiddemann W
Chronic systemic aspergillosis in a patient with acute myeloid leukemia.
Annals of hematology 1998;76(3-4):175-7.
1998: Wörmann B; Wulf G; Hiddemann W
[Clinical studies in oncology. Relevance, design, ethical considerations]
Medizinische Klinik (Munich, Germany : 1983) 1998;93(3):181-9.
1998: Behre G; Link H; Maschmeyer G; Meyer P; Paaz U; Wilhelm M; Hiddemann W
Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients.
Annals of hematology 1998;76(2):73-80.
1998: Wulf G G; Jahns-Streubel G; Nobiling R; Strutz F; Hemmerlein B; Hiddemann W; Wörmann B
Renin in acute myeloid leukaemia blasts.
British journal of haematology 1998;100(2):335-7.
1998: Liersch T; Gatzemeier W; Scharnberg P; Jürgens B; Wörmann B; Becker H; Rauschecker H F; Hiddemann W; Wulf G G
[Detection of disseminated carcinoma cells in bone marrow and peripheral blood in primary breast cancer with RT/PCR of parathyroid hormone-related protein (PTHrP)]
Langenbecks Archiv für Chirurgie. Supplement. Kongressband. Deutsche Gesellschaft für Chirurgie. Kongress 1998;115(Suppl I):277-80.
1997: Berkovic D; Fleer E A; Breass J; Pförtner J; Schleyer E; Hiddemann W
The influence of 1-beta-D-arabinofuranosylcytosine on the metabolism of phosphatidylcholine in human leukemic HL 60 and Raji cells.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11(12):2079-86.
1997: Schleyer E; Kühn S; Rührs H; Unterhalt M; Kaufmann C C; Kern W; Braess J; Sträubel G; Hiddemann W
Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11 Suppl 5():S15-21.
1997: Schoch C; Haase D; Fonatsch C; Haferlach T; Löffler H; Schlegelberger B; Hossfeld D K; Becher R; Sauerland M C; Heinecke A; Wörmann B; Büchner T; Hiddemann W
The significance of trisomy 8 in de novo acute myeloid leukaemia: the accompanying chromosome aberrations determine the prognosis. German AML Cooperative Study Group.
British journal of haematology 1997;99(3):605-11.
1997: Binder C; Binder L; Marx D; Schauer A; Hiddemann W
Deregulated simultaneous expression of multiple glucose transporter isoforms in malignant cells and tissues.
Anticancer research 1997;17(6D):4299-304.
1997: Wörmann B; Wulf G G; Griesinger F; Hiddemann W
[Sensitive detection of disseminated tumor cells--prognostic significance and therapeutic approaches]
Der Internist 1997;38(11):1083-91.
1997: Alves F; Hiddemann W
[Tyrosine kinase inhibitors. An approach to pathogenesis-oriented tumor therapy]
Der Internist 1997;38(11):1074-82.
1997: Braess J; Reich K; Willert S; Strutz F; Neumann C; Hiddemann W; Wörmann B
Mucocutaneous autoimmune syndrome following fludarabine therapy for low-grade non-Hodgkin's lymphoma of B-cell type (B-NHL).
Annals of hematology 1997;75(5-6):227-30.
1997: Haferlach T; Winkemann M; Ramm-Petersen L; Meeder M; Schoch R; Weber-Matthiesen K; Schlegelberger B; Schoch C; Ludwig W D; Hiddemann W; Löffler H
New insights into the biology of Philadelphia-chromosome-positive acute lymphoblastic leukaemia using a combination of May-Grünwald-Giemsa staining and fluorescence in situ hybridization techniques at the single cell level.
British journal of haematology 1997;99(2):452-9.
1997: Buske C; Twiling A; Gogowski G; Schreiber K; Feuring-Buske M; Wulf G G; Hiddemann W; Wörmann B
In vitro activation of low-grade non-Hodgkin's lymphoma by murine fibroblasts, IL-4, anti-CD40 antibodies and the soluble CD40 ligand.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11(11):1862-7.
1997: Berkovic D; Hiddemann W; Kuduz J; Fleer E A
Expression of two 50 kDa proteins is associated with sensitivity towards etherlipid analogues in the human leukaemia cell line HL 60.
European journal of cancer (Oxford, England : 1990) 1997;33(11):1875-80.
1997: Haferlach T; Hiddemann W
[Liver involvement in hematologic diseases]
Der Internist 1997;38(10):977-83.
1997: Dreyling M H; Bullinger L; Ott G; Stilgenbauer S; Müller-Hermelink H K; Bentz M; Hiddemann W; Döhner H
Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma.
Cancer research 1997;57(20):4608-14.
1997: Humpe A; Riggert J; Vehmeyer K; Troff C; Hiddemann W; Köhler M; Wörmann B
Comparison of CD34+ cell numbers and colony growth before and after cryopreservation of peripheral blood progenitor and stem cell harvests: influence of prior chemotherapy.
Transfusion 1997;37(10):1050-7.
1997: Binder C; Binder L; Kroemker M; Schulz M; Hiddemann W
Influence of cycloheximide-mediated downregulation of glucose transport on TNF alpha-induced apoptosis.
Experimental cell research 1997;236(1):223-30.
1997: Buske C; Hannig H; Hiddemann W; Bodemer W
Human herpesvirus-8 (HHV-8) DNA associated with anaplastic large cell lymphoma of the B-cell type in an HIV-1-positive patient.
International journal of cancer. Journal international du cancer 1997;73(2):303-4.
1997: Reiter-Theil S; Hiddemann W
["Medical Ethics Patient Forum". Results of a model project]
Medizinische Klinik (Munich, Germany : 1983) 1997;92(9):552-7.
1997: Jahns-Streubel G; Reuter C; Auf der Landwehr U; Unterhalt M; Schleyer E; Wörmann B; Büchner T; Hiddemann W
Activity of thymidine kinase and of polymerase alpha as well as activity and gene expression of deoxycytidine deaminase in leukemic blasts are correlated with clinical response in the setting of granulocyte-macrophage colony-stimulating factor-based priming before and during TAD-9 induction therapy in acute myeloid leukemia.
Blood 1997;90(5):1968-76.
1997: Micke O; Schäfer U; Wörmann B; Hiddemann W; Willich N
Circadian variations of interleukin-2 receptors, serum thymidine kinase and beta-2-microglobulin in patients with non-Hodgkin's lymphoma and normal controls.
Anticancer research 1997;17(4B):3007-10.
1997: Hiddemann W; Maschmeyer G; Link H; Helmerking M; Adam D
[Therapy of infections in patients with acute leukemia]
Medizinische Klinik (Munich, Germany : 1983) 1997;92(7):406-9.
1997: Linke B; Bolz I; Fayyazi A; von Hofen M; Pott C; Bertram J; Hiddemann W; Kneba M
Automated high resolution PCR fragment analysis for identification of clonally rearranged immunoglobulin heavy chain genes.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11(7):1055-62.
1997: Berkovic D; Lüders S; Goeckenjan M; Hiddemann W; Fleer E A
Differential regulation of phospholipase A2 in human leukemia cells by the etherphospholipid analogue hexadecylphosphocholine.
Biochemical pharmacology 1997;53(11):1725-33.
1997: Ivancevic V; Wörmann B; Nauck C; Sandrock D; Munz D L; Hiddemann W; Emrich D
Somatostatin receptor scintigraphy in the staging of lymphomas.
Leukemia & lymphoma 1997;26(1-2):107-14.
1997: Verbeek W; Haase D; Schoch C; Hiddemann W; Wörmann B
Induction of a hematological and cytogenetic remission in a patient with a myelodysplastic syndrome secondary to Fanconi's anemia employing the S-HAM regimen.
Annals of hematology 1997;74(6):275-7.
1997: Spiekermann K; Wörmann B; Rumpf K W; Hiddemann W
Combination chemotherapy with CHOP for recurrent thrombotic thrombocytopenic purpura.
British journal of haematology 1997;97(3):544-6.
1997: Gahn B; Schäfer C; Neef J; Troff C; Feuring-Buske M; Hiddemann W; Wörmann B
Detection of trisomy 12 and Rb-deletion in CD34+ cells of patients with B-cell chronic lymphocytic leukemia.
Blood 1997;89(12):4275-81.
1997: Verbeek W; Wörmann B; Koch P; Aul C; Hinrichs H; Balleisen L; Rowe J M; Bennett J; Büchner T; Hiddemann W
S-HAM induction chemotherapy with or without GM-CSF in patients with high-risk myelodysplastic syndromes.
Annals of hematology 1997;74(5):205-8.
1997: Haase D; Feuring-Buske M; Schäfer C; Schoch C; Troff C; Gahn B; Hiddemann W; Wörmann B
Cytogenetic analysis of CD34+ subpopulations in AML and MDS characterized by the expression of CD38 and CD117.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11(5):674-9.
1997: Pott C; Hiddemann W
Purine analogs in the treatment of chronic lymphocytic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11 Suppl 2():S25-8.
1997: Legler T J; Fischer I; Dittmann J; Simson G; Lynen R; Humpe A; Riggert J; Schleyer E; Kern W; Hiddemann W; Köhler M
Frequency and causes of refractoriness in multiply transfused patients.
Annals of hematology 1997;74(4):185-9.
1997: Buske C; Gogowski G; Schreiber K; Rave-Fränk M; Hiddemann W; Wörmann B
Stimulation of B-chronic lymphocytic leukemia cells by murine fibroblasts, IL-4, anti-CD40 antibodies, and the soluble CD40 ligand.
Experimental hematology 1997;25(4):329-37.
1997: Reuter C; Schleyer E; Rolf C; Wörmann B; Büchner T; Hiddemann W
Differential effect of GM-CSF pretreatment on intracellular Ara-C metabolism in normal bone marrow mononuclear cells vs acute myeloid leukemia (AML) blasts.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11(4):561-71.
1997: Köhne C H; Wilke H; Hiddemann W; Bokemeyer C; Lohrmann H P; Bodenstein H; Preiss J; Rauschecker H; Hill H; Kaufer C; Fischer J T; Ohl U; Urbanitz D; Balleisen L; Schmoll H J
Phase II evaluation of 5-fluourouracil plus folinic acid and alpha 2b-interferon in metastatic colorectal cancer.
Oncology 1997;54(2):96-101.
1997: Buske C; Becker D; Feuring-Buske M; Hannig H; Wulf G; Schäfer C; Hiddemann W; Wörmann B
TGF-beta inhibits growth and induces apoptosis in leukemic B cell precursors.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11(3):386-92.
1997: Hiddemann W; Unterhalt M; Sack H
[Current status of therapy of follicular germ center lymphoma and mantel cell lymphoma]
Der Internist 1997;38(2):122-34.
1997: Büchner T; Hiddemann W; Wörmann B; Zühlsdorf M; Rottmann R; Innig G; Maschmeier G; Ludwig W D; Sauerland M C; Heinecke A
Hematopoietic growth factors in acute myeloid leukemia: supportive and priming effects.
Seminars in oncology 1997;24(1):124-31.
1997: Kern W; Schleyer E; Unterhalt M; Wörmann B; Büchner T; Hiddemann W
High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study.
Cancer 1997;79(1):59-68.
1997: Liersch T; Wörmann B; Rauschecker H F; Kaufmann C C; Hiddemann W; Becker H; Gatzemeier W
[Brief interdisciplinary oncology: a model for ambulatory, multimodal treatment of tumor patients]
Langenbecks Archiv für Chirurgie. Supplement. Kongressband. Deutsche Gesellschaft für Chirurgie. Kongress 1997;114():607-9.
1997: Wulf G G; Jürgens B; Liersch T; Gatzemeier W; Rauschecker H; Buske C; Hüfner M; Hiddemann W; Wörmann B
Reverse transcriptase/polymerase chain reaction analysis of parathyroid hormone-related protein for the detection of tumor cell dissemination in the peripheral blood and bone marrow of patients with breast cancer.
Journal of cancer research and clinical oncology 1997;123(9):514-21.
1997: Gahn B; Schäfer C; Neef J; Troff C; Feuring-Buske M; Hiddemann W; Wörmann B
Detection of trisomy 12 in CD34+ progenitor cells in a patient with B-cell chronic lymphocytic leukemia by fluorescence in situ hybridization.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8 Suppl 2():55-7.
1997: Koch P; Grothaus-Pinke B; Hiddemann W; Willich N; Reers B; del Valle F; Bodenstein H; Pfreundschuh M; Möller E; Kocik J; Parwaresch R; Tiemann M
Primary lymphoma of the stomach: three-year results of a prospective multicenter study. The German Multicenter Study Group on GI-NHL.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8 Suppl 1():85-8.
1996: Hiddemann W; Maschmeyer G; Runde V; Einsele H
[Prevention, diagnosis and therapy of infections in patients with malignant diseases]
Der Internist 1996;37(12):1212-24.
1996: Hiddemann W; Longo D L; Coiffier B; Fisher R I; Cabanillas F; Cavalli F; Nadler L M; De Vita V T; Lister T A; Armitage J O
Lymphoma classification--the gap between biology and clinical management is closing.
Blood 1996;88(11):4085-9.
1996: Berkovic D; Haase D; Hiddemann W; Fleer E A
Induction of resistance in the human leukemia cell line HL60 towards hexadecylphosphocholine and other ether phospholipid analogues.
Journal of experimental therapeutics & oncology 1996;1(6):368-75.
1996: Bertram J; Palfner K; Hiddemann W; Kneba M
Increase of P-glycoprotein-mediated drug resistance by hsp 90 beta.
Anti-cancer drugs 1996;7(8):838-45.
1996: Hiddemann W
[Classification of malignant lymphomas--current status and clinical implications]
Therapeutische Umschau. Revue thérapeutique 1996;53(11):816-9.
1996: Hoelzer D; Gökbuget N; Arnold R; Büchner T; Freund M; Gassmann W; Heil G; Hiddemann W; Löffler H; Lipp T; Ludwig W D; Maschmeyer G; Thiel E; Messerer D
[Acute lymphatic leukemia of the adult. Diagnosis, risk groups and therapy]
Der Internist 1996;37(10):994-1007.
1996: Braess J; Kern W; Unterhalt M; Kaufmann C C; Ramsauer B; Schüssler M; Kaeser-Fröhlich A; Hiddemann W; Schleyer E
Response to cytarabine ocfosfate (YNK01) in a patient with chronic lymphocytic leukemia refractory to treatment with chlorambucil/prednisone, fludarabine, and prednimustine/mitoxantrone.
Annals of hematology 1996;73(4):201-4.
1996: Berkovic D; Goeckenjan M; Lüders S; Hiddemann W; Fleer E A
Hexadecylphosphocholine inhibits phosphatidylinositol and phosphatidylcholine phospholipase C in human leukemia cells.
Journal of experimental therapeutics & oncology 1996;1(5):302-11.
1996: Wulf G G; Jahns-Streubel G; Strutz F; Basenau D; Hüfner M; Buske C; Wörmann B; Hiddemann W
Paraneoplastic hypokalemia in acute myeloid leukemia: a case of renin activity in AML blast cells.
Annals of hematology 1996;73(3):139-41.
1996: Hiddemann W; Schleyer E; Unterhalt M; Kern W; Büchner T
Optimizing therapy for acute myeloid leukemia based on differences in intracellular metabolism of cytosine arabinoside between leukemic blasts and normal mononuclear blood cells.
Therapeutic drug monitoring 1996;18(4):341-9.
1996: Gahn B; Haase D; Unterhalt M; Drescher M; Schoch C; Fonatsch C; Terstappen L W; Hiddemann W; Büchner T; Bennett J M; Wörmann B
De novo AML with dysplastic hematopoiesis: cytogenetic and prognostic significance.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10(6):946-51.
1996: Unterhalt M; Herrmann R; Tiemann M; Parwaresch R; Stein H; Trümper L; Nahler M; Reuss-Borst M; Tirier C; Neubauer A; Freund M; Kreuser E D; Dietzfelbinger H; Bodenstein H; Engert A; Stauder R; Eimermacher H; Landys K; Hiddemann W
Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10(5):836-43.
1996: Schleyer E; Kühn S; Rührs H; Unterhalt M; Kaufmann C C; Kern W; Braess J; Sträubel G; Hiddemann W
Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10(4):707-12.
1996: Fleer E A; Berkovic D; Grunwald U; Hiddemann W
Induction of resistance to hexadecylphosphocholine in the highly sensitive human epidermoid tumour cell line KB.
European journal of cancer (Oxford, England : 1990) 1996;32A(3):506-11.
1996: Hiddemann W; Unterhalt M; Wörmann B
[Therapy of low-grade non-Hodgkin lymphomas]
Praxis 1996;85(12):357-63.
1996: Braess J; Pförtner J; Kaufmann C C; Ramsauer B; Unterhalt M; Hiddemann W; Schleyer E
Detection and determination of the major metabolites of [3H]cytosine arabinoside by high-performance liquid chromatography.
Journal of chromatography. B, Biomedical applications 1996;676(1):131-40.
1996: Binder C; Marx D; Binder L; Schauer A; Hiddemann W
Expression of Bax in relation to Bcl-2 and other predictive parameters in breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(2):129-33.
1996: Hiddemann W
[Low-grade malignant non-Hodgkin lymphomas--current status and trends in therapy]
Therapeutische Umschau. Revue thérapeutique 1996;53(2):123-32.
1996: Hoelzer D; Ludwig W D; Thiel E; Gassmann W; Löffler H; Fonatsch C; Rieder H; Heil G; Heinze B; Arnold R; Hossfeld D; Büchner T; Koch P; Freund M; Hiddemann W; Maschmeyer G; Heyll A; Aul C; Faak T; Kuse R; Ittel T H; Gramatzki M; Diedrich H; Kolbe K; Fuhr H G; Fischer K; Schadeck-Gressel C; Weiss A; Strohscheer I; Metzner B; Fabry U; Gökbuget N; Völkers B; Messerer D; Uberla K
Improved outcome in adult B-cell acute lymphoblastic leukemia.
Blood 1996;87(2):495-508.
1996: Wulf G G; Edel G; Deneke B; Gottschalk U; Hiddemann W; Wörmann B
A cell-surface epitope associated with liver-preferential metastasis detected by the new monoclonal antibody 3H4 in the murine tumor model ER 15-P.
Journal of cancer research and clinical oncology 1996;122(8):476-82.
1995: Binder C; Marx D; Overhoff R; Binder L; Schauer A; Hiddemann W
Bcl-2 protein expression in breast cancer in relation to established prognostic factors and other clinicopathological variables.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6(10):1005-10.
1995: Palfner K; Kneba M; Hiddemann W; Bertram J
Short technical reports. Quantification of ribozyme-mediated RNA cleavage using silver-stained polyacrylamide gels.
BioTechniques 1995;19(6):926-9.
1995: Hiddemann W
Non-Hodgkin's lymphomas--current status of therapy and future perspectives.
European journal of cancer (Oxford, England : 1990) 1995;31A(13-14):2141-5.
1995: Linke B; Bolz I; Pott C; Hiddemann W; Kneba M
Use of UITma DNA polymerase improves the PCR detection of rearranged immunoglobulin heavy chain CDR3 junctions.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1995;9(12):2133-7.
1995: Gralow I; von Hornstein W F; Schleyer E; Hiddemann W
[Pharmacokinetics of buprenorphine in subcutaneous administration]
Anästhesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS 1995;30(7):412-6.
1995: Berkovic D; Grunwald U; Menzel W; Unger C; Hiddemann W; Fleer E A
Effects of hexadecylphosphocholine on membrane phospholipid metabolism in human tumour cells.
European journal of cancer (Oxford, England : 1990) 1995;31A(12):2080-5.
1995: Kneba M; Bolz I; Linke B; Hiddemann W
Analysis of rearranged T-cell receptor beta-chain genes by polymerase chain reaction (PCR) DNA sequencing and automated high resolution PCR fragment analysis.
Blood 1995;86(10):3930-7.
1995: Jahns-Streubel G; Reuter C; Unterhalt M; Schleyer E; Wörmann B; Büchner T; Hiddemann W
Blast cell proliferative activity and sensitivity to GM-CSF in vitro are associated with early response to TAD-9 induction therapy in acute myeloid leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1995;9(11):1857-63.
1995: Haase D; Feuring-Buske M; Könemann S; Fonatsch C; Troff C; Verbeek W; Pekrun A; Hiddemann W; Wörmann B
Evidence for malignant transformation in acute myeloid leukemia at the level of early hematopoietic stem cells by cytogenetic analysis of CD34+ subpopulations.
Blood 1995;86(8):2906-12.
1995: Verbeek W; Pies A; Humpe A; Grove D; Troff C; Kunze E; Hiddemann W; Wörmann B
Mobilization of CD34-positive tumour cells in a patient with testicular mixed germ cell tumour.
British journal of haematology 1995;90(4):947-50.
1995: Feuring-Buske M; Haase D; Könemann S; Troff C; Grove D; Hiddemann W; Wörmann B
Trisomy 4 in 'stem cell-like' leukemic cells of a patient with AML.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1995;9(8):1318-20.
1995: Schleyer E; Reinhardt J; Unterhalt M; Hiddemann W
Highly sensitive coupled-column high-performance liquid chromatographic method for the separation and quantitation of the diastereomers of leucovorin and 5-methyltetrahydrofolate in serum and urine.
Journal of chromatography. B, Biomedical applications 1995;669(2):319-30.
1995: Schleyer E; Braess J; Ramsauer B; Unterhalt M; Kaufmann C; Wilde S; Schüssler M; Hiddemann W
Pharmacokinetics of Ara-CMP-Stearate (YNK01): phase I study of the oral Ara-C derivative.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1995;9(6):1085-90.
1995: Linke B; Pyttlich J; Tiemann M; Suttorp M; Parwaresch R; Hiddemann W; Kneba M
Identification and structural analysis of rearranged immunoglobulin heavy chain genes in lymphomas and leukemias.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1995;9(5):840-7.
1995: Köhne C H; Hiddemann W; Schüller J; Weiss J; Lohrmann H P; Schmitz-Hübner U; Bodenstein H; Schöber C; Wilke H; Grem J
Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(5):1201-8.
1995: Pott-Hoeck C; Hiddemann W
Purine analogs in the treatment of low-grade lymphomas and chronic lymphocytic leukemias.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6(5):421-33.
1995: Palfner K; Kneba M; Hiddemann W; Bertram J
Improvement of hammerhead ribozymes cleaving mdr-1 mRNA.
Biological chemistry Hoppe-Seyler 1995;376(5):289-95.
1995: Kneba M; Eick S; Herbst H; Pott C; Bolz I; Dallenbach F; Hiddemann W; Stein H
Low incidence of mbr bcl-2/JH fusion genes in Hodgkin's disease.
The Journal of pathology 1995;175(4):381-9.
1995: Ramsauer B; Braess J; Unterhalt M; Kaufmann C C; Hiddemann W; Schleyer E
Highly sensitive high-performance liquid chromatographic assay for 1-beta-D-arabinofuranosylcytosine-5'-stearyl phosphate (cytarabine-ocfosfate).
Journal of chromatography. B, Biomedical applications 1995;665(1):183-92.
1995: Bertram J; Palfner K; Killian M; Brysch W; Schlingensiepen K H; Hiddemann W; Kneba M
Reversal of multiple drug resistance in vitro by phosphorothioate oligonucleotides and ribozymes.
Anti-cancer drugs 1995;6(1):124-34.
1995: Hiddemann W; Buchner T
Rationale for high-dose chemotherapy and application of haematopoietic growth factors in acute myeloid leukaemia.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6 Suppl 4():27-31.
1995: Verbeek W; Vehmeyer K; Wörmann B; Hiddemann W
The effect of stem-cell factor, interleukin-3 and erythropoietin on in vitro erythropoiesis in myelodysplastic syndromes.
Journal of cancer research and clinical oncology 1995;121(6):338-42.
1994: Hiddemann W; Unterhalt M
Current status and future perspectives in the treatment of low-grade non-Hodgkin's lymphomas.
Blood reviews 1994;8(4):225-33.
1994: Wörmann B; Reuter C; Zühlsdorf M; Büchner T; Hiddemann W
Experimental basis for the use of recombinant human granulocyte-macrophage colony-stimulating factor in patients with acute myeloid leukemia.
Seminars in oncology 1994;21(6 Suppl 16):39-43.
1994: Hiddemann W; Wörmann B; Reuter C; Schleyer E; Zühlsdorf M; Böckmann A; Büchner T
New perspectives in the treatment of acute myeloid leukemia by hematopoietic growth factors.
Seminars in oncology 1994;21(6 Suppl 16):33-8.
1994: Reiter A; Schrappe M; Ludwig W D; Hiddemann W; Sauter S; Henze G; Zimmermann M; Lampert F; Havers W; Niethammer D
Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86.
Blood 1994;84(9):3122-33.
1994: Link H; Maschmeyer G; Meyer P; Hiddemann W; Stille W; Helmerking M; Adam D
Interventional antimicrobial therapy in febrile neutropenic patients. Study Group of the Paul Ehrlich Society for Chemotherapy.
Annals of hematology 1994;69(5):231-43.
1994: Buske C; Hiddemann W; Wörmann B
Proliferation of human leukemic pre-B cells induced by human bone marrow stromal cells and murine fibroblasts.
Cell biology international 1994;18(11):1049-58.
1994: Binder C; Hiddemann W
Programmed cell death--many questions still to be answered.
Annals of hematology 1994;69(2):45-55.
1994: Kneba M; Bolz I; Linke B; Bertram J; Rothaupt D; Hiddemann W
Characterization of clone-specific rearrangement T-cell receptor gamma-chain genes in lymphomas and leukemias by the polymerase chain reaction and DNA sequencing.
Blood 1994;84(2):574-81.
1994: Maschmeyer G; Link H; Hiddemann W; Meyer P; Helmerking M; Eisenmann E; Schmitt J; Adam D
Pulmonary infiltrations in febrile patients with neutropenia. Risk factors and outcome under empirical antimicrobial therapy in a randomized multicenter study.
Cancer 1994;73(9):2296-304.
1994: Hiddemann W; Unterhalt M; Koch P; Nahler M; Herrmann R
New aspects in the treatment of advanced low-grade non-Hodgkin's lymphomas: prednimustine/mitoxantrone versus cyclophosphamide/vincristine/prednisone followed by interferon alfa versus observation only--a preliminary update of the German Low-Grade Lymphoma Study Group.
Seminars in hematology 1994;31(2 Suppl 3):32-5.
1994: Hiddemann W
[Hematopoietic growth factors. Current status of therapy]
Der Internist 1994;35(4):395-400.
1994: Maschmeyer G; Link H; Hiddemann W; Meyer P; Helmerking M; Eisenmann E; Schmitt J; Adam D
[Empirical antimicrobial therapy in neutropenic patients. Results of a multicenter study by the Infections in Hematology Study Group of the Paul Ehrlich Society]
Medizinische Klinik (Munich, Germany : 1983) 1994;89(3):114-23.
1994: Schleyer E; Kamischke A; Kaufmann C C; Unterhalt M; Hiddemann W
New aspects on the pharmacokinetics of mitoxantrone and its two major metabolites.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1994;8(3):435-40.
1994: Reuter C; Auf der Landwehr U; Schleyer E; Zühlsdorf M; Ameling C; Rolf C; Wörmann B; Büchner T; Hiddemann W
Modulation of intracellular metabolism of cytosine arabinoside in acute myeloid leukemia by granulocyte-macrophage colony-stimulating factor.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1994;8(2):217-25.
1994: Hiddemann W; Pott-Hoeck C
Fludarabine in the management of malignant lymphomas.
Drugs 1994;47 Suppl 6():50-6.
1993: Schöber C; Papageorgiou E; Harstrick A; Bokemeyer C; Mügge A; Stahl M; Wilke H; Poliwoda H; Hiddemann W; Köhne-Wömpner C H
Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer.
Cancer 1993;72(7):2242-7.
1993: Hiddemann W; Unterhalt M; Pott C; Wörmann B; Sandford D; Freund M; Engert A; Gassmann W; Holtkamp W; Seufert J
Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphomas: a phase II study of the German Low-Grade Non-Hodgkin's Lymphoma Study Group.
Seminars in oncology 1993;20(5 Suppl 7):28-31.
1993: Hoelzer D; Thiel E; Ludwig W D; Löffler H; Büchner T; Freund M; Heil G; Hiddemann W; Maschmeyer G; Völkers B
Follow-up of the first two successive German multicentre trials for adult ALL (01/81 and 02/84). German Adult ALL Study Group.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1993;7 Suppl 2():S130-4.
1993: Hiddemann W
[Chronic lymphatic leukemia. Current status and perspectives]
Der Internist 1993;34(6):534-41.
1993: Schleyer E; Lohmann R; Rolf C; Gralow A; Kaufmann C C; Unterhalt M; Hiddemann W
Column-switching solid-phase trace-enrichment high-performance liquid chromatographic method for measurement of buprenorphine and norbuprenorphine in human plasma and urine by electrochemical detection.
Journal of chromatography 1993;614(2):275-83.
1993: Kusnierz-Glaz C R; Normann D; Weinberg R; Fuchs R; Flasshove M; Hiddemann W; van de Loo J; Büchner T
Subcutaneous low dose arabinosyl-cytosine and oral idarubicin in high risk adult acute myelogenous leukemia.
Hematological oncology 1993;11(2):73-80.
1993: Hiddemann W; Griesinger F
Preclinical aspects and therapeutic perspectives of acute and chronic leukemias.
Current opinion in oncology 1993;5(1):13-25.
1993: Hiddemann W; Aul C; Maschmeyer G; Schönrock-Nabulsi R; Ludwig W D; Bartholomäus A; Bettelheim P; Becker K; Balleisen L; Lathan B
High-dose versus intermediate dose cytosine arabinoside combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age adjusted randomized comparison.
Leukemia & lymphoma 1993;10 Suppl():133-7.
1993: Wörmann B; Safford M; Könemann S; Büchner T; Hiddemann W; Terstappen L W
Detection of aberrant antigen expression in acute myeloid leukemia by multiparameter flow cytometry.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1993;131():185-96.
1993: Hiddemann W; Harbott J; Ludwig W D; Ritter J; Nehmer A; Reiter A; Kolkmeyer A; Laing T; Riehm H
DNA aneuploidy in childhood acute lymphoblastic leukemia: relation to clinical determinants and prognosis within four consecutive BFM trials.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1993;131():113-21.
1993: Büchner T; Hiddemann W; Wörmann B; Rottmann R; Maschmeyer G; Ludwig W D; Zühlsdorf M; Buntkirchen K; Sander A; Aswald J
The role of GM-CSF in the treatment of acute myeloid leukemia.
Leukemia & lymphoma 1993;11 Suppl 2():21-4.
1992: Hiddemann W; Schleyer E; Unterhalt M; Zühlsdorf M; Rolf C; Reuter C; Kewer U; Uhrmeister C; Wörmann B; Büchner T
Differences in the intracellular pharmacokinetics of cytosine arabinoside (AraC) between circulating leukemic blasts and normal mononuclear blood cells.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1992;6(12):1273-80.
1992: Büchner T; Hiddemann W; Schaefer U W; Löffler H; Maschmeyer G; Ludwig W D; Aul C; Lathan B; Heinecke A
Combined effect of very early intensification and prolonged post-remission chemotherapy in patients with AML.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1992;6 Suppl 4():68-70.
1992: Behre G; Schedel I; Nentwig B; Wörmann B; Essink M; Hiddemann W
Endotoxin concentration in neutropenic patients with suspected gram-negative sepsis: correlation with clinical outcome and determination of anti-endotoxin core antibodies during therapy with polyclonal immunoglobulin M-enriched immunoglobulins.
Antimicrobial agents and chemotherapy 1992;36(10):2139-46.
1992: Terstappen L W; Safford M; Unterhalt M; Könemann S; Zurlutter K; Piechotka K; Drescher M; Aul C; Büchner T; Hiddemann W
Flow cytometric characterization of acute myeloid leukemia: IV. Comparison to the differentiation pathway of normal hematopoietic progenitor cells.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1992;6(10):993-1000.
1992: Ehninger G; Proksch B; Wanner T; Schuler U; Busch F W; Schmidt H; Schleyer E; Jaschonek K; Hiddemann W
Intracellular cytosine arabinoside accumulation and cytosine arabinoside triphosphate formation in leukemic blast cells is inhibited by etoposide and teniposide.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1992;6(6):582-7.
1992: Hiddemann W; Ruelfs C; Ottensmeier C; Rückle H; Musch E; Koch O; van de Loo J
Interleukin-2 followed by fluorouracil and folinic acid in refractory colorectal cancer--results of a clinical phase II study.
Seminars in oncology 1992;19(2 Suppl 3):225-7.
1992: Schmoll H J; Köhne-Wömpner C H; Hiddemann W; Knipp H; Wilke H; Bodenstein H; Schöffski P; Bokemeyer C; Lohrmann H P; Preiss J
Interferon alpha-2b, 5-fluorouracil, and folinic acid combination therapy in advanced colorectal cancer: preliminary results of a phase I/II trial.
Seminars in oncology 1992;19(2 Suppl 3):191-6.
1992: Schmoll H J; Hiddemann W; Rustum Y; Köhne-Wömpner C H
The emerging role for biomodulation of antineoplastic agents.
Seminars in oncology 1992;19(2 Suppl 3):1-3.
1992: Hiddemann W; Kiehl M; Zühlsdorf M; Busemann C; Schleyer E; Wörmann B; Büchner T
Granulocyte-macrophage colony-stimulating factor and interleukin-3 enhance the incorporation of cytosine arabinoside into the DNA of leukemic blasts and the cytotoxic effect on clonogenic cells from patients with acute myeloid leukemia.
Seminars in oncology 1992;19(2 Suppl 4):31-7.
1992: Freund M; Diedrich H; Ganser A; Gramatzki M; Heil G; Heyll A; Henke M; Hiddemann W; Haas R; Kuse R
Treatment of relapsed or refractory adult acute lymphocytic leukemia.
Cancer 1992;69(3):709-16.
1992: Freund M; Wunsch-Zeddies S; Schäfers M; Wysk J; Seidel I; Hiddemann W; Hanauske A R; Link H; Schmoll H J; Poliwoda H
Prednimustine and mitoxantrone (PmM) in patients with low-grade malignant non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), and prolymphocytic leukemia (PLL).
Annals of hematology 1992;64(2):83-7.
1992: Terstappen L W; Safford M; Könemann S; Loken M R; Zurlutter K; Büchner T; Hiddemann W; Wörmann B
Flow cytometric characterization of acute myeloid leukemia. Part II. Phenotypic heterogeneity at diagnosis.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1992;6(1):70-80.
1992: Büchner T; Hiddemann W; Wörmann B; Löffler H; Maschmeyer G; Hossfeld D; Ludwig W D; Nowrousian M; Aul C; Schaefer U W
Longterm effects of prolonged maintenance and of very early intensification chemotherapy in AML: data from AMLCG.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1992;6 Suppl 2():68-71.
1992: Hoelzer D; Thiel E; Ludwig W D; Löffler H; Büchner T; Freund M; Heil G; Hiddemann W; Maschmeyer G; Völkers B
The German multicentre trials for treatment of acute lymphoblastic leukemia in adults. The German Adult ALL Study Group.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1992;6 Suppl 2():175-7.
1991: Wörmann B; Hiddemann W; Frisch J; Zühlsdorf M; Rottmann R; Boeckmann A; Reuter C; Freire E A; Innig G; Schulz G
In vitro and in vivo effects of rh GM-CSF in acute myeloid leukemia (AML).
Behring Institute Mitteilungen 1991;(90):28-38.
1991: Büchner T; Hiddemann W; Koenigsmann M; Zühlsdorf M; Wörmann B; Boeckmann A; Freire E A; Innig G; Maschmeyer G; Ludwig W D
Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse.
Blood 1991;78(5):1190-7.
1991: Hiddemann W; Essink M E; Fegeler W; Zühlsdorf M; Sauerland C; Büchner T
Antifungal treatment by amphotericin B and 5-fluorocytosine delays the recovery of normal hematopoietic cells after intensive cytostatic therapy for acute myeloid leukemia.
Cancer 1991;68(1):9-14.
1991: Büchner T; Hiddemann W; Löffler G; Gassmann W; Maschmeyer G; Heit W; Hossfeld D; Weh H; Ludwig W D; Thiel E
Improved cure rate by very early intensification combined with prolonged maintenance chemotherapy in patients with acute myeloid leukemia: data from the AML Cooperative Group.
Seminars in hematology 1991;28(3 Suppl 4):76-9.
1991: Hiddemann W; Aul C; Maschmeyer G; Schönrock-Nabulsi R; Ludwig W D; Bartholomäus A; Bettelheim P; Becker K; Balleisen L; Lathan B
High-dose versus intermediate-dose cytarabine combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age-adjusted randomized comparison.
Seminars in hematology 1991;28(3 Suppl 4):35-8.
1991: Hiddemann W; Rottmann R; Wörmann B; Thiel A; Essink M; Ottensmeier C; Freund M; Büchner T; van de Loo J
Treatment of advanced chronic lymphocytic leukemia by fludarabine. Results of a clinical phase-II study.
Annals of hematology 1991;63(1):1-4.
1991: Hiddemann W
Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens.
Annals of hematology 1991;62(4):119-28.
1991: Terstappen L W; Könemann S; Safford M; Loken M R; Zurlutter K; Büchner T; Hiddemann W; Wörmann B
Flow cytometric characterization of acute myeloid leukemia. Part 1. Significance of light scattering properties.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1991;5(4):315-21.
1991: Koenigsmann M; Hiddemann W; Büchner T
Reversible leukaemic regrowth under GM-CSF treatment after chemotherapy for AML.
Leukemia research 1991;15(1):37-41.
1991: Hiddemann W; Unterhalt M; Koch P; Nahler M; Herrmann R; van de Loo J
alpha Interferon maintenance therapy in patients with low-grade non-Hodgkin's lymphomas after cytoreductive chemotherapy with prednimustine and mitoxantrone.
European journal of cancer (Oxford, England : 1990) 1991;27 Suppl 4():S37-9.
1990: Hiddemann W; Unterhalt M; Koch P; Nahler M; van de Loo J
Treatment of low-grade non-Hodgkin's lymphoma by cytoreductive chemotherapy with prednimustine/mitoxantrone followed by interferon alpha-2b maintenance: results of a clinical phase II study.
Seminars in oncology 1990;17(6 Suppl 10):20-3.
1990: Hiddemann W; Büchner T; Heil G; Schumacher K; Diedrich H; Maschmeyer G; Ho A D; Planker M; Gerith-Stolzenburg S; Donhuijsen-Ant R
Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytosine arabinoside and mitoxantrone (HAM).
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1990;4(9):637-40.
1990: Hiddemann W; Schmitz N; Pfreundschuh M; Pflüger K H; Ollech-Chwoyka J; Tirier C; Maschmeyer G; Kirchner H; Wagner T; Koch P
Treatment of refractory Hodgkin's disease with high-dose cytosine arabinoside and mitoxantrone in combination. Results of a clinical phase II study of the German Hodgkin Study Group.
Cancer 1990;66(5):838-43.
1990: Hiddemann W; Schleyer E; Uhrmeister C; Aul C H; Maschmeyer G; Heinecke A; Büchner T
High-dose versus intermediate-dose cytosine arabinoside in combination with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia--preliminary clinical and pharmacological data of a randomized comparison.
Cancer treatment reviews 1990;17(2-3):279-85.
1990: Silling-Engelhardt G; Hiddemann W
[Paraneoplastic syndromes of the hematopoietic cell system]
Der Internist 1990;31(8):520-5.
1990: Stenzinger W; Blömker A; Hiddemann W; van de Loo J
Treatment of refractory multiple myeloma with the vincristine-adriamycin-dexamethasone (VAD) regimen.
Blut 1990;61(2-3):55-9.
1990: Buechner T; Hiddemann W; Koenigsmann M; Zuehlsdorf M; Woermann B; Boeckmann A; Aguion Freire E; Innig G; Maschmeyer G; Ludwig W D
Recombinant human GM-CSF following chemotherapy in high-risk AML.
Bone marrow transplantation 1990;6 Suppl 1():131-4.
1990: von Eiff M; Essink M; Roos N; Hiddemann W; Büchner T; van de Loo J
Hepatosplenic candidiasis, a late manifestation of Candida septicaemia in neutropenic patients with haematologic malignancies.
Blut 1990;60(4):242-8.
1990: Hiddemann W; Martin W R; Sauerland C M; Heinecke A; Büchner T
Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1990;4(3):184-8.
1990: Hiddemann W; Büchner T
Treatment strategies in acute myeloid leukemia (AML). B. Second line treatment.
Blut 1990;60(3):163-71.
1990: Buechner T; Hiddemann W
Treatment strategies in acute myeloid leukemia (AML). A. First-line chemotherapy.
Blut 1990;60(2):61-7.
1990: Maschmeyer G; Link H; Hiddemann W; Meyer P; Helmerking M; Adam D
Interventional antimicrobial strategy in febrile neutropenic patients. Results of a multicenter study in 1,260 patients with hematological malignancies. The Interventional Antimicrobial Strategy Study Group, Paul Ehrlich Society for Chemotherapy.
Onkologie 1990;13(1):38-42.
1990: Essink M E; Hiddemann W; von Eiff M; Büchner T; van de Loo J
Effect of antifungal therapy on hematological recovery after intensive antileukemic chemotherapy.
Haematology and blood transfusion 1990;33():558-9.
1990: von Eiff M; Essink M; Roos N; Schmidt H; Hiddemann W; Büchner T; van de Loo J
Hepatosplenic candidiasis in acute leukemias.
Haematology and blood transfusion 1990;33():555-7.
1990: Kusnierz-Glaz C; Reiser M; Hagemeister B; Büchner T; Hiddemann W; van de Loo J
Magnetic resonance imaging follow-up in patients with acute leukemia during induction chemotherapy.
Haematology and blood transfusion 1990;33():351-6.
1990: Krehmeier C; Zühlsdorf M; Büchner T; Hiddemann W
Synergistic cytotoxicity of cytosine arabinoside and mitoxantrone for K562 and CFU-GM.
Haematology and blood transfusion 1990;33():129-32.
1990: Hiddemann W; Zühlsdorf M; Wörmann B; Koenigsmann M; Büchner T
Changing response of clonogenic myeloid leukemia blasts to granulocyte-macrophage colony-stimulating factor (GM-CSF) during anti-leukemic therapy--a case report on the basis of a clinical phase II trial.
Leukemia research 1990;14(4):347-52.
1990: Büchner T; Hiddemann W; Koenigsmann M; Zuehlsdorf M; Woermann B; Boeckmann A; Aguion Freire E; Innig G; Maschmeyer G; Ludwig W D
Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy for acute leukemias at higher age or after relapse.
Haematology and blood transfusion 1990;33():724-31.
1990: Hiddemann W; Aul H C; Maschmeyer G; Urbanitz D; Lathan B; Reichle A; Köppler H; Donhuijsen-Ant R; Ludwig W D; Grüneisen T
Proposal for the classification of relapsed and refractory acute myeloid leukemias as the basis for an age-adjusted randomized comparison of sequentially applied high-dose versus intermediate-dose cytosine arabinoside in combination with mitoxantrone (S-HAM).
Haematology and blood transfusion 1990;33():604-10.
1990: Freund M; De Boben M; Diedrich H; Ganser A; Heil G; Heyll A; Henke M; Hiddemann W; Knauf U; Koch P
Treatment of relapsed acute lymphocytic leukemia in adults.
Haematology and blood transfusion 1990;33():432-6.
1990: Büchner T; Hiddemann W; Blasius S; Koch P; Maschmeyer G; Tirier C; Sodomann H; Kuse R; Thiel E; Ludwig W D
Adult AML: the role of chemotherapy intensity and duration. Two studies of the AML Cooperative Group.
Haematology and blood transfusion 1990;33():261-6.
1990: Büchner T; Hiddemann W; Maschmeyer G; Ludwig W; Löffler H; Nowrousian M; Aul C; Heinecke A
How to improve therapy for adult acute myeloid leukemia: studies of the AML Cooperative Group in the Federal Republic of Germany.
Journal of cancer research and clinical oncology 1990;116(1):97-9.
1990: Hiddemann W; Wörmann B; Messerer D; Springefeld R; Büchner T
Analysis of the cellular DNA and RNA content in acute leukemias by flow cytometry.
Journal of cancer research and clinical oncology 1990;116(5):507-12.
1989: Hiddemann W
What's new in malignant tumors in acquired immunodeficiency disorders?
Pathology, research and practice 1989;185(6):930-4.
1989: Schleyer E; Ehninger G; Zühlsdorf M; Proksch B; Hiddemann W
Detection and separation of intracellular 1-beta-D-arabinofuranosylcytosine-5-triphosphate by ion-pair high-performance liquid chromatography.
Journal of chromatography 1989;497():109-20.
1989: Hiddemann W; Urbanitz D; Preusser P; Achterrath W; Büchner T
Treatment of refractory acute myeloid leukemia with mAMSA and VP 16-213 in combination: results of a clinical phase I/II study.
Hematological oncology 1989;7(4):267-73.
1989: Hiddemann W; Büchner T; van de Loo J
[Principles of relapse therapy in acute myeloid leukemia]
Deutsche medizinische Wochenschrift (1946) 1989;114(15):599-605.
1989: Hiddemann W; Aul C; Maschmeyer G; Lathan B; Köppler H; Hoffmann R; Grüneisen T; Donhuijsen-Ant R; Ludwig W D; Balleisen L
Age related randomized comparison of sequentially applied high-dose versus intermediate dose cytosine arabinoside in combination with mitoxantrone (S-HAM) in the treatment of relapsed and refractory acute myeloid leukemia: study design and preliminary results.
Onkologie 1989;12(1):4-6.
1988: Büchner T; Hiddemann W; Zühlsdorf M; Koenigsmann M; Böckmann A; van de Loo J; Schulz G
Human recombinant granulocyte macrophage colony stimulating factor (GM-CSF) treatment of patients with acute leukemias in aplasia and at high risk of early death.
Behring Institute Mitteilungen 1988;(83):309-12.
1988: von Eiff M; Essink M; Fegeler W; Schellong S; Schmidt H; Hiddemann W; Büchner T; van de Loo J
[Clinical course and risk factors in patients with generalized mycoses]
Schweizerische medizinische Wochenschrift 1988;118(16):584-91.
1988: Hiddemann W; Büchner T; Essink M; Koch O; Stenzinger W; van de Loo J
High-dose cytosine arabinoside and mitoxantrone: preliminary results of a pilot study with sequential application (S-HAM) indicating a high antileukemic activity in refractory acute leukemias.
Onkologie 1988;11(1):10-2.
1987: Hiddemann W; Kreutzmann H; Straif K; Ludwig W D; Mertelsmann R; Planker M; Donhuijsen-Ant R; Lengfelder E; Arlin Z; Büchner T
High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia.
Seminars in oncology 1987;14(2 Suppl 1):73-7.
1987: Hiddemann W; Kreutzmann H; Straif K; Ludwig W D; Mertelsmann R; Donhuijsen-Ant R; Lengfelder E; Arlin Z; Büchner T
High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia.
Blood 1987;69(3):744-9.
1987: Maschmeyer G; Hiddemann W; Kreutzmann H; Wendt F
Combined chemotherapy with m-amsacrine in high-risk patients with acute non-lymphocytic leukemia.
Onkologie 1987;10(1):18-21.
1987: Büchner T; Urbanitz D; Hiddemann W; Koch P; Pielken H J; Kuse R; Mohr A; Maschmeyer G; Kreutzmann H; Wendt F
[Alternatives and further development of therapy of acute myeloid leukemia in adults. Update of West German multicenter studies]
Onkologie 1987;10(1):14-6.
1987: Hiddemann W; Kreutzmann H; Donhuijsen-Ant R; Planker M; Wendt F C; Büchner T
High-dose cytosine arabinoside and mitoxantrone (HAM) for the treatment of refractory acute lymphoblastic leukemia.
Onkologie 1987;10(1):11-2.
1987: Büchner T; Hiddemann W; Urbanitz D; Kreutzmann H; Maschmeyer G; Wendt F; Kuse R; Mohr A; Gassmann W; Löffler H
Postinduction and preremission chemotherapy alternatives for adult AML: three multicenter studies of the AML Cooperative Group.
Haematology and blood transfusion 1987;30():57-63.
1987: Hiddemann W; Kreutzmann H; Straif K; Ludwig W D; Fuhr H J; Donhuijsen-Ant R; Lengfelder E; Büchner T
Phase I/II trial of high-dose cytosine arabinoside and mitoxantrone in adult refractory acute myeloid leukemia.
Haematology and blood transfusion 1987;30():336-8.
1986: Hiddemann W; Kreutzmann H; Straif K; Ludwig W D; Donhuijsen-Ant R; Lengfelder E; Arlin Z; Büchner T
High-dose cytosine-arabinoside and mitoxantrone in refractory acute myeloid leukemia: a clinical phase I/II-study.
Onkologie 1986;9(3):144-6.
1986: Büchner T; Urbanitz D; Hiddemann W; Koch P; Pielken H J; Kuse R; Mohr A; Maschmeyer G; Kreutzmann H; Wendt F
[Acute myeloid leukemia (AML) in adults. Further development of therapy based on clinical phase II and phase III studies]
Onkologie 1986;9(2):83-91.
1985: Büchner T; Urbanitz D; Hiddemann W; Rühl H; Ludwig W D; Fischer J; Aul H C; Vaupel H A; Kuse R; Zeile G
Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1985;3(12):1583-9.
1985: Hiddemann W; Kreutzmann H; Ludwig W D; Aul H C; Donhuijsen-Ant R; Lengfelder E; Büchner T
Mitozantrone and high-dose cytarabine in refractory adult acute myeloid leukaemia.
Lancet 1985;2(8453):508-9.
1985: Urbanitz D; Pielken H J; Koch P; Büchner T; Hiddemann W; Heinecke A; Wendt F; Maschmeier G; van de Loo J
Immunotherapy with allogeneic neuraminidase-treated blasts for maintenance in acute myelogenous leukemia (AML). Significant prolongation of remission duration in patients receiving at least 3 cycles of therapy.
Onkologie 1985;8(3):157-9.
1984: Büchner T; Urbanitz D; Emmerich B; Fischer J; Heinecke A; Hiddemann W; Pfreundschuh M; Rühl H; Wendt F
Long-term remission in acute myelogenous leukaemia.
Lancet 1984;1(8376):571.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Wolfgang Hiddemann

Research Profile (preview)

Procedures

Disorders

Chemicals & Drugs

Concepts & Ideas

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Wolfgang Hiddemann (preview)

All Publications